European drug report 2017 trends and developments. by unknown
2017
EN
Trends and Developments
European 
Drug 
Report
IS
S
N
 1
9
7
7
-9
8
6
0
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
2017
Trends and Developments
European 
Drug 
Report
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
 l Legal notice
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected 
by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use 
of the data contained in this document. The contents of this publication do not necessarily reflect the official 
opinions of the EMCDDA’s partners, any EU Member State or any agency or institution of the European Union.
Europe Direct is a service to help you find answers to your questions about the European Union.
Freephone number (*): 00 800 6 7 8 9 10 11
(*) The information given is free, as are most calls (though some operators, phone boxes or hotels may 
charge you).
More information on the European Union is available on the internet (http://europa.eu).
This report is available in Bulgarian, Spanish, Czech, Danish, German, Estonian, Greek, English, French, Croatian, 
Italian, Latvian, Lithuanian, Hungarian, Dutch, Polish, Portuguese, Romanian, Slovak, Slovenian, Finnish, Swedish, 
Turkish and Norwegian. All translations were made by the Translation Centre for the Bodies of the European Union.
Luxembourg: Publications Office of the European Union, 2017
© European Monitoring Centre for Drugs and Drug Addiction, 2017 
Reproduction is authorised provided the source is acknowledged.
Recommended citation: 
European Monitoring Centre for Drugs and Drug Addiction (2017), European Drug Report 2017: Trends and 
Developments, Publications Office of the European Union, Luxembourg.
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal 
Tel. +351 211210200 
info@emcdda.europa.eu I www.emcdda.europa.eu
twitter.com/emcdda I facebook.com/emcdda
Print ISBN 978-92-9497-074-9 ISSN 1977-9860 doi:10.2810/46831 TD-AT-17-001-EN-C 
PDF ISBN 978-92-9497-095-4 ISSN 2314-9086 doi:10.2810/610791 TD-AT-17-001-EN-N 
EPUB ISBN 978-92-9497-083-1 ISSN 2314-9086 doi:10.2810/144609 TD-AT-17-001-EN-E
Printed in Belgium
Printed on elemental chlorine-free bleached paper (ECF)
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
 5  Preface
 9  Introductory note and acknowledgements
11 I  COMMENTARY The European drug situation in 2017
19 I  CHAPTER 1  Drug supply and the market
41 I  CHAPTER 2  Drug use prevalence and trends
61 I  CHAPTER 3 Drug-related harms and responses
83 I  ANNEX National data tables
 l Contents
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
5 l Preface
It is our great pleasure to introduce the European Drug Report 2017: Trends and 
Developments, the EMCDDA’s flagship publication, which provides the latest data on the 
drug situation and responses in Europe. We offer you a package of information and 
analysis that is rich and multi-layered, based on the most recent data and statistics 
provided by our national partners.
The 2017 report is accompanied by a new set of national overviews, in the form of 30 
Country Drug Reports, presenting accessible online summaries of national drug trends 
and developments in policy and practice taking place in European countries.
While this publication provides an annual update of the drug phenomenon in Europe, it 
also builds on the triennial EU Drug Markets Report, published in 2016. And later this year 
it will be complemented by the first dedicated EU report on health and social responses to 
drugs.
At the EMCDDA, we are tasked with collecting data and ensuring that it is fit for purpose. In 
doing so, we strive to provide the best possible evidence and contribute to realising our 
vision of a healthier and more secure Europe. As a top-level overview and analysis of 
drug-related trends and developments, we intend this report to be a useful tool for 
European and national policymakers and planners who wish to base their strategies and 
interventions on the most recent information available. In line with our objective to deliver 
high quality services to our stakeholders, this latest report will allow access to data that 
can be used for multiple purposes: as baseline and follow-up data for policy and service 
evaluations; to give context and help define priorities for strategic planning; to enable 
comparisons to be made between national situations and datasets; and to highlight 
emerging threats and issues.
This year´s report highlights some potentially worrying changes in the market for illicit 
opioids, the substances that continue to be associated with a high level of morbidity and 
mortality in Europe. We note the overall increase in opioid-related overdose deaths as well 
as the increasing reports of problems linked with opioid substitution medications and new 
synthetic opioids. As the drug phenomenon continues to evolve, so too must Europe’s 
response to drugs. The framework for concerted action, set out in the European drug 
strategy 2013–20, allows for this. A new drug action plan for the period 2017–20 has been 
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proposed by the European Commission and is being discussed by the European 
Parliament and the Council. It builds on the findings of the mid-term assessment of the 
current EU drug strategy and the final evaluation of the 2013–17 action plan. The 
EMCDDA’s work to support evidence-informed drug policymaking in Europe is reflected in 
these key policy documents.
In conclusion, we wish to thank our colleagues in the Reitox network of national focal 
points, who alongside national experts, provide most of the data that underpin this 
publication. We also acknowledge the contribution of numerous European research 
groups, without which this analysis would be less rich. The report also benefits from 
collaboration with our European partners: the European Commission, Europol, the 
European Medicines Agency and the European Centre for Disease Prevention and Control.
Laura d’Arrigo
Chair, EMCDDA Management Board
Alexis Goosdeel
Director, EMCDDA
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9 l Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the 
candidate country Turkey, and Norway in the form of a national reporting package.
The purpose of the current report is to prove an overview and summary of the European 
drug situation and responses to it. The statistical data reported here relate to 2015 (or the 
last year available). Analysis of trends is based only on those countries providing sufficient 
data to describe changes over the period specified. Statistical significance is tested at the 
0.05 level, unless otherwise stated. The reader should also be aware that monitoring 
patterns and trends in a hidden and stigmatised behaviour such as drug use is both 
practically and methodologically challenging. For this reason, multiple sources of data are 
used for the purposes of analysis in this report. Although considerable improvements can 
be noted, both nationally and in respect to what is possible to achieve in a European level 
analysis, the methodological difficulties in this area must be acknowledged. Caution is 
therefore required in interpretation, in particular when countries are compared on any 
single measure. Caveats and qualifications relating to the data are to be found in the 
online version of this report and in the Statistical Bulletin, where detailed information on 
methodology, qualifications on analysis and comments on the limitations in the 
information set available can be found. Information is also available on the methods and 
data used for European level estimates, where interpolation may be used.
The EMCDDA would like to thank the following for their help in producing this report:
 the heads of the Reitox national focal points and their staff;
 the services and experts within each Member State that collected the raw data for this 
report;
 the members of the Management Board and the Scientific Committee of the EMCDDA;
 the European Parliament, the Council of the European Union — in particular its 
Horizontal Working Party on Drugs — and the European Commission;
 the European Centre for Disease Prevention and Control (ECDC), the European 
Medicines Agency (EMA) and Europol;
 the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and 
Crime, the WHO Regional Office for Europe, Interpol, the World Customs Organisation, 
the European School Survey Project on Alcohol and Other Drugs (ESPAD), the Sewage 
Analysis Core Group Europe (SCORE), the European Drug Emergencies Network (Euro-
DEN);
 the Translation Centre for the Bodies of the European Union and the Publications Office 
of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network 
is comprised of national focal points in the EU Member States, the candidate country 
Turkey, Norway and at the European Commission. Under the responsibility of their 
governments, the focal points are the national authorities providing drug information 
to the EMCDDA. The contact details of the national focal points may be found on the 
EMCDDA website.
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Commentary
The European drug situation 
in 2017
This report offers a snapshot of the 
European drug situation based on the 
latest available information from EU 
monitoring activities. A European 
overview of the drug market, drug use 
and harms and responses forms the 
body of this report. This is accompanied 
by 30 complementary national reports 
as well as extensive online data and 
methodological information.
This introductory section features a 
short analytical comment on some of 
the key themes emerging from this 
year’s data. As the drug problems facing 
Europe are increasingly influenced by 
and interact with developments 
occurring internationally, the analysis 
gains value by being placed in a wider 
global context. For two important topics, 
cannabis use among young people and 
changes in the opioid market, the 
current European situation and its 
evolution is compared and contrasted 
with that in North America, and notable 
similarities and differences are found to 
exist.
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 l Comparing substance use behaviours among EU and US school students
In this respect, the release in 2016 of two new major 
school surveys of students (aged around 15 to 16) is 
helpful, as it allows comparisons to be made between 
patterns of cannabis and other substance use among 
European and American students. Encouragingly, in both 
regions, the most recent data show a decline in use of 
tobacco and, albeit to a lesser extent, alcohol; though 
trends in cannabis use appear more stable. However, in 
respect to levels and patterns of use of these substances, 
important differences exist between European and 
American students.
In Europe, measures of cannabis use are lower than those 
found in the United States, and cannabis use is less 
commonly reported than tobacco use. In contrast, US 
students’ use of cannabis exceed their use of tobacco, 
which is very low. Levels of alcohol consumption also 
differ, with more European students reporting alcohol 
consumption, and more intense patterns of drinking, than 
their American peers.
Further analysis of both the similarities and differences in 
the students’ substance use is needed to explore the 
relative influence of the social, contextual and regulatory 
factors on the choices made by young people. 
Understanding, for example, what has led to the reductions 
in cigarette smoking observed in both the United States 
and Europe may offer insights for addressing the use of 
other substances, such as cannabis. It is also important to 
remember that differences exist in how substances are 
consumed. In Europe, for example, in contrast to the 
United States, cannabis is often smoked in combination 
with tobacco, and this is likely to have implications for 
public health policies.
 l Do international cannabis policy developments have implications for Europe?
Recent changes in the regulatory framework for cannabis 
occurring in parts of the Americas have generated interest 
among policymakers and the public in Europe. These 
developments have been quite diverse, and there is a need 
to wait for robust evaluations before the relative costs and 
benefits of differing cannabis policy approaches can be 
assessed. Furthermore, the extent to which developments 
occurring elsewhere can be directly transferable to the 
European context is unclear.
Considerable diversity on attitudes to cannabis regulation 
and use exists within the European Union’s 28 Member 
States; with current approaches ranging from restrictive 
models, to the tolerance of some forms of personal use. 
Nonetheless, a lively debate is now taking place, with 
issues such as permitting the production of cannabis for 
personal use, and making cannabis available for treating 
medical conditions, of growing interest in some countries.
Regardless of any wider impact on drug policy, the 
existence of a commercially regulated cannabis market in 
some countries outside Europe is fuelling innovation and 
product development, for example, vaporisers, E-liquids 
and edible products. It is possible that some of these 
developments will impact on consumption patterns in 
Europe, underlining the importance of behavioural 
monitoring in this area and the need to evaluate the 
potential health implications of any changes in future 
consumption patterns.
The European cannabis market has already changed 
considerably in recent years, in part driven by a move to 
more domestic production. The historically high overall 
potency levels of both resin and herbal cannabis available 
in Europe, reached in recent years, are still observed. The 
drug also continues to be associated with health problems, 
and is responsible for the greatest share of reported new 
entrants to drug treatment in Europe. For all these reasons, 
understanding trends in cannabis use and related harms is 
important to the debate on what constitutes the most 
appropriate policy responses to this drug.
 Understanding trends  
 in cannabis use and related  
 harms is important 
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 l Europe’s stimulants market: is cocaine availability on the rise?
Europe’s most commonly used illicit stimulant drugs — 
cocaine, MDMA and the amphetamines — continue be 
associated with diverse and geographically differentiated 
patterns of use, and all have higher reported purity levels 
than a decade ago. This sector of the illicit drug market has 
grown in complexity, with the ready availability of new 
stimulants including cathinones and phenethylamines. 
Last year’s report highlighted increases in the availability 
and use of high-dose MDMA tablets, and this trend is still 
evident in the most recent data. The high MDMA content 
now found in seized tablets would suggest that producers 
are having no difficulty acquiring the precursor chemicals 
necessary to manufacture the drug. Seizures data also 
indicate that Europe remains an important producer for the 
global MDMA market.
Multiple indicators, including wastewater monitoring, 
seizures, and price and purity data, suggest that the 
availability of cocaine may once more be on the rise in 
parts of Europe. This drug has historically been the most 
commonly used illicit stimulant in a number of countries, 
mainly located in the south and west of Europe. New data 
reported here supports this, with increasing seizures noted 
along the established trafficking routes to the main 
European markets for this drug. In contrast, in northern 
and central Europe, amphetamine and, to a lesser extent, 
methamphetamine play a more significant role in the drug 
market than cocaine. For the amphetamines, a number of 
developments reported previously continue to be of 
concern. Among these are changes in the availability of 
precursors and in the routes of synthesis; the expansion of 
the methamphetamine market; and some evidence of 
increasing levels of injection and related harm.
 l Injecting declines but remains a challenge for public health policies
Information from drug treatment and other sources 
indicates that the overall long-term trend in injecting as a 
route of administration continues to be downward. Among 
heroin users entering specialised drug treatment for the 
first time in their life, for example, reports of injecting are 
now at their lowest point for over a decade, although 
considerable variation exists between countries. Some of 
the health-harm indicators linked to this route of 
administration, particularly rates of new HIV diagnoses 
attributed to injecting drug use, have shown a parallel 
decline. This does not mean, however, that concerns have 
disappeared in this area. Although the 1 233 new HIV 
infections reported in 2016 were the lowest for more than 
two decades, this still represents a significant public health 
problem. Moreover, there have been recent outbreaks in 
some vulnerable populations and among users who are 
injecting stimulants and new psychoactive substances.
There is also evidence that blood-borne infections are 
often diagnosed relatively late among people who inject 
drugs, compared with other groups, thereby reducing the 
opportunity for successful intervention. Late diagnosis is 
also important in respect to HCV infection, which is often 
NB: Trends in last month substance use among 15- to 16-year-old school students in Europe and the United States. European averages (unweighted) are based on 
data from 21 EU countries and Norway (source: ESPAD). US averages are based on samples of 10th grade students (source: Monitoring the Future).
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offending among those receiving it. Good clinical practice 
together with an understanding of how prescription 
opioids are diverted from their legitimate use, and how to 
reduce this, are therefore important if the clear health 
benefits that accrue from this treatment approach are not 
to be undermined.
 l Highly potent synthetic opioids: a growing health threat
In both Europe and North America, the recent emergence 
of highly potent new synthetic opioids, mostly fentanyl 
derivatives, is causing considerable concern. Since 2012, 
the EU Early Warning System has been receiving an 
increasing number of reports of these substances and of 
harms caused by them. These substances have been sold 
on online markets, and also on the illicit market. They have 
sometimes been sold as, or mixed with, heroin, other illicit 
drugs and even counterfeit medicines. Highly potent 
synthetic opioids present serious health risks, not only to 
those who use them, but also to those involved in their 
manufacture, as well as postal workers and law 
enforcement officers. With only small volumes needed to 
produce many thousands of doses, these substances are 
easy to conceal and transport. This poses a considerable 
challenge for drug control agencies. At the same time, they 
present a potentially attractive and profitable commodity 
for organised crime.
found at high rates among those who have injected drugs. 
In the past few years, the possibilities for the treatment of 
viral hepatitis have improved greatly, with the arrival of a 
new generation of medicines, which are highly effective. 
The eradication of this disease can now be seen as both an 
opportunity and a challenge for general healthcare 
providers and specialised drug services.
 l The changing nature of the opioid problem
Comparison with developments in North America is also 
relevant to an analysis of Europe’s opioid drug problem. A 
review of the data presented in this report suggests that, 
while the overall EU situation remains different, some 
parallels do exist.
The latest data show that heroin use still accounts for the 
majority, around 80 %, of new opioid-related treatment 
demands in Europe. In addition, the overall decline in 
treatment demand related to heroin, observed since 2007, 
is no longer evident. Of particular concern is the increasing 
European estimate for drug overdose deaths, which has 
now risen for the third consecutive year; heroin is 
implicated in many of these deaths.
North America has also experienced considerable 
morbidity and mortality associated with the misuse of 
prescription opioids, rising levels of heroin use and, most 
recently, the emergence of highly potent synthetic opioids, 
in particular fentanyl derivatives. One difference between 
the two regions is that in Europe, very few clients 
presenting for specialised drug treatment do so for 
addiction to opioid pain medicines. This probably reflects 
the different regulatory frameworks and approaches to 
marketing and prescribing that exist between Europe and 
the North America. However, the possibility of under-
reporting cannot be dismissed, as Europeans experiencing 
problems with prescription medicines may access different 
services than those used by illicit drug users. Medicines 
used for opioid substitution treatment, however, now play 
a more significant role in treatment demands and health 
harms in a number of European countries. Overall, 
non-heroin opioids account for around a fifth of all opioid-
related demands to specialised drug services. The role that 
synthetic opioids, such as methadone, play in overdose 
deaths is difficult to quantify at EU level, but in many 
countries these substances are now important, and in a 
few countries they predominate. Reducing the misuse of 
medicines, including those used for opioid substitution 
treatment, is a growing challenge for many European 
healthcare providers. A strong evidence base supports the 
appropriate use of opioid substitution medicines, which 
has been shown to reduce morbidity, mortality and 
 Highly potent synthetic opioids  
 present serious health risks 
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AT A GLANCE — ESTIMATES OF DRUG USE IN THE EUROPEAN UNION
NB: For the complete set of data and information on the methodology,  see the accompanying online Statistical Bulletin.
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In Europe, problems related to highly potent synthetic 
opioids appear to be growing, as indicated by increasing 
reports of non-fatal intoxications and deaths received by 
the Early Warning System. In early 2017, the EMCDDA 
carried out risk-assessment exercises on the fentanyl 
derivatives acryloylfentanyl and furanylfentanyl. These 
substances are being considered for control at European 
level, and a number of other drugs in this category are 
currently under scrutiny.
 l The changing face of new psychoactive substances
This year’s analysis suggests that while responses, both in 
Europe and elsewhere, may be having an impact on the 
emergence of new substances, the new psychoactive 
substances phenomenon continues to represent a 
considerable public health challenge. Although new drugs 
were reported to the EU Early Warning System at a rate of 
one per week in 2016, the overall number of new 
detections was lower than in previous years. This may be a 
positive sign, especially if this decline is sustained. 
However, other data are less encouraging, with no strong 
indication that the overall availability of new psychoactive 
substances has reduced. Moreover, even if the pace at 
which new substances are being introduced may be 
slowing, the overall number of substances available on the 
market continues to grow. There are also signs that some 
classes of new psychoactive substances, notably synthetic 
cathinones and synthetic cannabinoids, are now 
establishing a foothold in the drug market.
There are a number of reasons that may explain why the 
pace of new substances appearing on the market may be 
slowing. Some European countries have introduced 
blanket bans, generic and analogue based legislation and 
other measures to target the producers and retailers of 
new psychoactive substances. This has created a more 
restrictive legal environment, in which there may be less 
incentive for producers to engage in a ‘cat and mouse 
game’ with regulators, in which innovation is used to keep 
ahead of legal controls.
In addition, much of the supply of new psychoactive 
substances to Europe originates in China, and new 
controls there may also have had some impact on 
availability in the European Union.
In parts of Europe, control measures targeting high street 
shops appear to have impacted on access to new 
psychoactive substances. Sales of these substances have 
become more clandestine, with online access and the illicit 
drug market now playing a more important role than in the 
past. In this context, the legal status of new substances, 
especially when they are sold alongside illicit drugs, may 
be less important and, correspondingly, be a less powerful 
driver for product innovation.
 l New psychoactive substances: cheap intoxicants for marginalised and chronic drug users
Negative consumer attitudes may also have impacted on 
demand for new psychoactive substances. Prevention, 
harm reduction and the reporting of adverse 
consequences appear to have influenced the perception 
among young people that new substances are relatively 
safe legal alternatives to established illicit drugs. In spite of 
this, however, among more chronic and marginalised user 
populations, there is also evidence that the availability and 
use of these substances may be growing.
Problematic use of new psychoactive substances is 
becoming more apparent in certain settings and among 
some vulnerable populations. Injecting cathinone use, for 
example, among current and former opioid users, has been 
associated with increased levels of both physical and 
mental health problems.
Synthetic cannabinoids also are a growing concern. 
Despite some pharmacological similarities, these drugs 
should not be confused with cannabis products. Synthetic 
cannabinoids are often highly potent substances, which 
can have serious, potentially lethal, consequences. There is 
evidence to suggest that in parts of Europe, synthetic 
cannabinoids are now being consumed as cheap and 
powerful intoxicants by marginalised groups such as the 
homeless. Difficulties in detection mean that synthetic 
cannabinoids have become a particular problem in some 
European prisons, resulting in serious implications for 
prisoner health and security.
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Drug supply and the market
In the global context, Europe is an 
important market for drugs, supplied 
with both domestically produced drugs 
and drugs trafficked from other world 
regions. South America, West Asia and 
North Africa are important source areas 
for illicit drugs entering Europe, while 
China is a source country for new 
psychoactive substances. In addition, 
some drugs and precursors are 
transited through Europe en route to 
other continents. Europe is also a 
producing region for cannabis and 
synthetic drugs, with cannabis mostly 
produced for local consumption, while 
some of the synthetic drugs are 
manufactured for export to other parts 
of the world.
Sizeable markets for cannabis, heroin and amphetamines 
have existed in many European countries since the 1970s 
and 1980s. Over time, other substances also established 
themselves — including MDMA and cocaine in the 1990s. 
The European drug market continues to evolve, with the 
last decade witnessing the emergence of a wide range of 
new psychoactive substances. Recent changes in the illicit 
drug market, largely linked to globalisation and new 
technology, include innovation in drug production and 
trafficking methods, the establishment of new trafficking 
routes and online markets.
Monitoring drug markets, supply and laws
The analysis presented in this chapter draws on 
reported data on drug seizures, drug precursor 
seizures and stopped shipments, dismantled drug 
production facilities, drug laws, drug law offences, 
retail drug prices, purity and potency. In some cases, 
the absence of seizure data from key countries 
makes the analysis of trends difficult. A range of 
factors can influence trends, including user 
preferences, changes in production and trafficking, 
law enforcement activity levels and priorities and the 
effectiveness of interdiction measures. Full data sets 
and methodological notes can be found in the online 
Statistical Bulletin.
Also presented here are data on notifications and 
seizures of new psychoactive substances reported to 
the EU Early Warning System by the national 
partners of the EMCDDA and Europol. As this 
information is drawn from case reports rather than 
routine monitoring systems, seizure estimates 
represent a minimum. A full description of the Early 
Warning System can be found on the EMCDDA 
website under Action on new drugs.
 l Drug markets: emergence of internet-based supply
Illicit drug markets link consumers to producers through 
chains of intermediaries. These complex systems generate 
large sums of money at all levels of the market. A 
conservative estimate values the retail market for illicit 
drugs in the European Union at EUR 24 billion in 2013 
(likely range EUR 21 billion to EUR 31 billion).
Chapter 1
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
20
European Drug Report 2017: Trends and Developments
 l Drug seizures: over one million in Europe
Over one million seizures of illicit drugs are reported 
annually in Europe. Most of these are small quantities of 
drugs confiscated from users, however, multi-kilogram 
consignments of drugs seized from traffickers and 
producers account for most of the total quantity of drugs 
seized.
Cannabis is the most commonly seized drug, accounting 
for over 72 % of seizures in Europe (Figure 1.1). Cocaine 
ranks second overall (9 %), followed by amphetamines 
(5 %), heroin (5 %) and MDMA (2 %).
The last decade has seen the development of online 
marketplaces, facilitated by the emergence of new internet 
technologies, which exist in parallel with the physical drugs 
market. Some online vendors utilise the surface web, 
typically retailing non-controlled precursor chemicals, new 
psychoactive substances or medicines, which may be 
falsified or counterfeit. Other vendors work on the deep 
web, through darknet markets, supported by technologies 
that hide buyer and seller identities. These markets share 
characteristics with legitimate online marketplaces such 
as eBay and Amazon, and customers can search for and 
compare products and vendors. Various strategies are 
used to conceal both transactions and the physical 
locations of servers. These include anonymisation services, 
such as Tor and I2P, that hide a computer’s internet 
protocol address; cryptocurrencies, such as bitcoin and 
litecoin, for making relatively untraceable payments; and 
encrypted communication between market participants. 
Reputation systems also play a role in regulating vendors 
on the markets.
Most sales on darknet markets are drug-related. A recent 
study, exploring sales on 16 major darknet markets 
between 2011 and 2015, estimated that drug sales were 
responsible for more than 90 % of the total economic 
revenue of global darknet marketplaces. Nearly half (46 %), 
of all darknet drug sales reportedly originated from 
vendors based in Europe, representing an estimated 
EUR 80 million over the period of the study. The main 
European source countries, in order of sales volumes, were 
Germany, the Netherlands and the United Kingdom, with 
stimulants, in particular MDMA and cocaine, accounting 
for most of the sales revenue.
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FIGURE 1.1
Number of reported drug seizures, breakdown by drug, 2015
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In 2015, more than 60 % of all drug seizures in the 
European Union were reported by just 3 countries, Spain, 
France and the United Kingdom; considerable numbers of 
seizures were also reported by Belgium, Denmark, 
Germany, Greece, Italy and Sweden. It should also be 
noted that recent data on the number of seizures are not 
available for the Netherlands or for Poland and Finland. 
These gaps in the data add uncertainty to the analysis.
The large numbers of drug seizures reported by Turkey 
reflects both its significant consumer market and its 
position on drug trafficking routes between the European 
Union, the Middle East and Asia.
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CANNABIS
 l Recent decline in quantity of herbal cannabis seized
Herbal cannabis (marijuana) and cannabis resin (hashish) 
are the two main cannabis products found on the 
European drugs market, while cannabis oil is 
comparatively rare. Cannabis products account for the 
largest share (38 %) of the illicit drug retail market in 
Europe, with an estimated value of EUR 9.3 billion (likely 
range EUR 8.4 billion to EUR 12.9 billion). Herbal cannabis 
consumed in Europe is both cultivated domestically and 
trafficked from external countries. The herbal cannabis 
produced in Europe is mostly cultivated indoors. Most of 
the cannabis resin is imported, mainly from Morocco. 
Recent reports indicate changes in cannabis trafficking 
routes, with increases in the trafficking of both herbal 
cannabis and cannabis oil from the western Balkans, 
notably Albania, linked to increased cannabis cultivation in 
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those countries. In addition, evidence suggests that Libya 
has become a major hub for the trafficking of resin to 
various destinations including Europe.
In 2015, 732 000 seizures of cannabis products were 
reported in the European Union including 404 000 of 
herbal cannabis, 288 000 of cannabis resin and 19 000 of 
cannabis plants. The quantity of cannabis resin seized, 
however, is more than 6 times that of herbal cannabis 
(536 tonnes versus 89 tonnes). This is partially a 
consequence of cannabis resin being trafficked in volume 
over large distances and across national borders, making it 
more vulnerable to interdiction. In the analysis of the 
quantity of cannabis seized, a small number of countries 
are particularly important due to their location on major 
cannabis trafficking routes. Spain, for example, as a major 
point of entry for cannabis resin produced in Morocco, 
reported more than 70 % of the total quantity seized in 
Europe in 2015 (Figure 1.2).
The number of seizures of herbal cannabis in Europe has 
exceeded that of cannabis resin since 2009, with relatively 
stable trends in the number of both resin and herbal 
cannabis seizures since 2011 (Figure 1.3). An estimated 
135 tonnes of herbal cannabis was seized in Europe in 
2015, a decrease of 38 % compared with the 217 tonnes 
seized in 2014. Notable declines were reported in Belgium, 
Greece and Italy. A similar decrease in the quantity of 
herbal cannabis seized in Turkey is also evident from 2013. 
A number of factors may be behind this overall drop in 
Europe. These may include initiatives to tackle large-scale 
production in countries outside the European Union, such 
as Albania; increased focus on domestic cultivation rather 
than trafficking; changes in the way seizures are registered, 
and changing law enforcement priorities in some 
countries. In the latest data, the quantity of cannabis resin 
seized in the European Union has remained relatively 
stable since 2009.
FIGURE 1.2
Seizures of cannabis resin and herbal cannabis, 2015 or most recent year
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Seizures of cannabis plants may be regarded as an 
indicator of the production of the drug within a country. 
Because of reporting differences between countries, data 
on cannabis plant seizures must be considered with 
caution. Nevertheless, the number of plants seized has 
shown a long-term increase, from 1.5 million plants in 
2002 to 3.3 million in 2014, rising sharply to 11.4 million 
plants in 2015, with a large increase in the number of 
plants seized reported from the Netherlands. This trend 
may reflect changes in law enforcement priorities, with 
cannabis cultivation more intensively targeted.
In 2015, 335 seizures of cannabis oil were reported, with 
Greece and Turkey seizing the largest quantities.
FIGURE 1.3
Trends in number of cannabis seizures and quantity of cannabis seized: resin and herb 
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Analysis of indexed trends among those countries 
reporting consistently shows a large increase in the 
potency (content of tetrahydrocannabinol, THC) of both 
herbal cannabis and cannabis resin between 2006 and 
2014, stabilising in 2015. Drivers of this increasing 
potency may include the introduction of intensive 
production techniques within Europe and, more recently, 
the introduction of high-potency plants and new 
techniques in Morocco. The most recent data suggest that 
resin and herb have similar prices, whereas on average, 
resin has a higher potency.
 The number of seizures  
 of herbal cannabis in Europe  
 has exceeded that of cannabis  
 resin since 2009 
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opioids seized by law enforcement agencies in European 
countries in 2015 included opium and the medicines 
morphine, methadone, buprenorphine, tramadol and 
fentanyl (Table 1.1). Some medicinal opioids may be 
diverted from legitimate pharmaceutical supplies, while 
others such as the 27 kilograms of morphine powder 
seized in 2015, are illicitly manufactured.
Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or in neighbouring Iran or Pakistan. 
 l Continuing increase in heroin purity
Heroin is the most common opioid on the European drug 
market, with an estimated retail value of EUR 6.8 billion 
(likely range EUR 6.0 billion to EUR 7.8 billion). Historically, 
imported heroin has been available in Europe in two forms, 
the more common of which is brown heroin (its chemical 
base form), originating mainly from Afghanistan. Far less 
common is white heroin (a salt form), which in the past 
came from South-East Asia, but now may also be 
produced in Afghanistan or neighbouring countries. Other 
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FIGURE 1.4
Number of heroin seizures and quantity seized: trends and 2015 or most recent year
>5
1–5
<1
No data
Turkey
0 5 1510
Other countries
Quantity of heroin seized (tonnes)
Number of heroin  
seizures (thousands)
Tonnes
Number of seizures
EU EU, Turkey and Norway
France United Kingdom Other countries
GreeceRomaniaTurkey Italy
NB: Number of seizures for the 10 countries with highest values. 
7.8
0.8
2.2
12.3
2.4 3.1
8.1
3.0
1.2
4.7
20 000
30 000
40 000
50 000
60 000
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
0
5
10
15
20
25
30
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
25
Chapter 1 I Drug supply and the market
Since the 1970s, illicit opioid production in Europe has 
been limited to homemade poppy products produced in 
some eastern countries. However, the discovery of two 
laboratories converting morphine to heroin in Spain and 
one in the Czech Republic in recent years suggests that a 
small amount of heroin is manufactured in Europe.
Heroin enters Europe along four main trafficking routes. 
The two most important are the ‘Balkan route’ and the 
‘southern route’. The first of these runs through Turkey, into 
Balkan countries (Bulgaria, Romania or Greece) and on to 
central, southern and western Europe. An offshoot of the 
Balkan route involving Syria and Iraq has also emerged. 
The southern route, where shipments from Iran and 
Pakistan enter Europe by air or sea, either directly or 
transiting through African countries, has gained 
importance in recent years. Other routes include the 
‘northern route’ and a route through the southern 
Caucasus and across the Black Sea.
Following a decade of relative stability, markets in a 
number of European countries experienced reduced 
heroin availability in 2010/11. This is evident in the 
number of heroin seizures reported, which declined in the 
European Union from 2009 to 2014, before stabilising in 
2015. Between 2002 and 2013, the quantity of heroin 
seized within the European Union halved, from 10 to 
5 tonnes. After the seizure of 8.4 tonnes in 2014, a year 
when several countries reported large heroin seizures 
(100 kg and above), in 2015 the quantity of heroin seized 
in Europe (4.5 tonnes) returned to the levels registered in 
the early 2010s. After reaching around 13 tonnes in 2014, 
Turkish heroin seizures decreased to 8.3 tonnes in 2015 
— a figure still greater than all other European countries 
combined — while the number of seizures rose during the 
same period (Figure 1.4). Among those countries reporting 
consistently, indexed trends suggest that heroin purity 
continued to increase in Europe in 2015.
In addition to heroin, other opioid products are seized in 
European countries, but these represent a small fraction of 
the total seizures. The other opioids most commonly 
seized are the medicinal opioids buprenorphine, tramadol 
and methadone (see Table 1.1).
Opioid Number Quantity Number 
of countriesKilograms Litres Tablets
Methadone 1 566 31 8 60 472 17
Buprenorphine 3 377 4 68 419 17
Tramadol 2 467 690 080 12
Fentanyls (fentanyl, 
ocfentanil, carfentanil)
287 3 41 10
Morphine 775 27 8 837 15
Opium 293 734 14
Codeine 293 3 9 855 8
Oxycodone 16 0.0003 962 5
TABLE 1.1
Seizures of opioids other than heroin in 2015
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 l Stimulant seizures: regional variations
The main illicit stimulant drugs available in Europe are 
cocaine, amphetamine, methamphetamine and MDMA. 
The retail value of the stimulant market in the European 
Union is estimated to be worth between EUR 6.3 billion 
and EUR 10.2 billion. There are marked regional differences 
regarding which stimulant is most commonly seized 
(Figure 1.5), which are influenced by the location of entry 
ports and trafficking routes, major production centres and 
large consumer markets. Cocaine is the most frequently 
seized stimulant in many western and southern countries, 
closely reflecting where the drug enters Europe. 
Amphetamines seizures are predominant in northern and 
central Europe, with methamphetamine the most 
commonly seized stimulant in the Czech Republic, Latvia, 
Lithuania and Slovakia. MDMA is the most commonly 
seized stimulant drug in Croatia, Romania and Turkey.
 l Cocaine: recent increases in market indicators
In Europe, cocaine is available in two forms, the most 
common is cocaine powder (the salt form) and less 
commonly available is crack cocaine (free base), a 
smokeable form of the drug. Cocaine is produced from the 
leaves of the coca bush. The drug is produced mainly in 
Bolivia, Colombia and Peru. Cocaine is transported to 
Europe by various means, including passenger flights, air 
freight, postal services, private aircraft, yachts and 
maritime containers. The retail cocaine market in the 
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Most frequently seized stimulant drug in Europe, 2015 or most 
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FIGURE 1.6
Number of cocaine seizures and quantity seized: trends and 2015 or most recent year
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 The main illicit stimulant drugs  
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European Union is estimated to be worth a minimum of 
EUR 5.7 billion.
In total, around 87 000 seizures of cocaine were reported 
in the European Union in 2015. Together, Belgium, Spain, 
France, Italy and Portugal account for 78 % of the 
estimated 69.4 tonnes seized (Figure 1.6). The situation 
has remained relatively stable since 2007, although both 
the number of seizures and the quantity seized increased 
between 2014 and 2015 (see Figure 1.6). While Spain 
(22 tonnes) continues to be the country seizing the most 
cocaine, Belgium (17 tonnes) and France (11 tonnes) 
seized very large amounts in 2015, and notable increases 
in quantities seized, compared with the previous year, were 
reported by Belgium, Germany and Portugal. Overall, 
indexed trends suggest a small increase in the purity of 
cocaine in 2015.
Other coca products were seized in Europe in 2015, 
including 76 kilograms of coca leaves and 377 kilograms 
of coca paste. Seizures of coca paste suggest the 
existence of illicit laboratories producing cocaine 
hydrochloride in Europe. This is a new development as, to 
date, most of the cocaine laboratories found in Europe 
have been ‘secondary extraction facilities’, where cocaine 
is recovered from materials in which it had been 
incorporated (such as wines, clothes, plastics).
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 l Precursor chemicals: new alternatives for amphetamines available
Drug precursors are essential chemicals needed to 
manufacture illicit drugs. As many of these have legitimate 
uses, EU regulations schedule certain chemicals, and their 
trade is monitored and controlled. The availability of 
precursors has a large impact on the market and on the 
production methods used in illicit laboratories. In 2015, 
producers continued to circumvent control mechanisms by 
introducing non-scheduled chemicals to produce drug 
precursors close to production locations. This practice, 
however, increases the risk of detection, as more 
processing requires more chemicals and creates more 
waste.
Data on seizures and stopped shipments of drug 
precursors confirm the use of both scheduled and non-
scheduled substances in the production of illicit drugs in 
the European Union, in particular for amphetamines and 
MDMA (Table 1.2). The amphetamine precursor BMK 
(benzyl methyl ketone) was seized in large quantities in 
2015, with Polish authorities seizing 7 000 kilograms in a 
single shipment linked to production in the Netherlands. 
The control of the BMK precursor APAAN (alpha-
phenylacetoacetonitrile) in late 2013 appears to have had 
an impact, with seizures falling from 48 000 kilograms in 
2013 to 780 kilograms in 2015. However, this control 
measure appears to have prompted some innovative 
developments, with alternative chemicals such as APAA 
(alpha-phenylacetoacetamide) and glycidic derivatives of 
BMK reported for the first time in 2015.
Seizures of non-scheduled MDMA pre-precursors 
remained steady at around 5 500 kilograms. However, 
while safrole seizures were negligible, PMK seizures 
resumed, with the Netherlands reporting 622 kilograms in 
2015 compared to zero in 2014.
 l Amphetamine and methamphetamine: domestic production
Amphetamine and methamphetamine are synthetic 
stimulant drugs, often grouped under the umbrella term 
‘amphetamines’, and hence can be difficult to differentiate 
in some datasets. Over the last decade, seizures indicate 
that the availability of methamphetamine has increased, 
but it is still much lower than that of amphetamine.
Seizures Stopped shipments TOTALS
Precursor/pre-precursor Number Quantity Number Quantity Number Quantity
MDMA or related substances
PMK (litres) 6 622 0 0 6 622
Safrole (litres) 2 2 0 0 2 2
Piperonal (kg) 7 45 4 1 925 11 1 970
Glycidic derivatives of PMK (kg) 11 5 461 0 0 11 5 461
Amphetamine and methamphetamine
APAAN (kg) 10 778 0 0 10 778
BMK (litres) 17 1 029 0 0 17 1 029
PAA, phenylacetic acid (kg) 6 261 4 103 10 364
Ephedrine bulk (kg) 12 8 1 500 13 508
Pseudoephedrine bulk (kg) 8 32 0 0 8 32
APAA (kg) 1 201 0 0 1 201
Glycidic derivatives of BMK (kg) 5 14 0 0 5 14
TABLE 1.2
Summary of seizures and stopped shipments of precursors used for selected synthetic drugs produced in the European Union, 2015
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Both drugs are produced in Europe for the European 
market. There are indications that amphetamine 
production mainly takes place in Belgium, the Netherlands 
and Poland, and to a lesser extent in the Baltic States, 
Germany and Hungary. There are also indications that the 
final stage of production, the conversion of amphetamine 
base oil to amphetamine sulphate, is carried out in Europe.
Some amphetamine is also manufactured for export, 
principally to the Middle East, the Far East and Oceania. 
Seizures of amphetamine tablets with a ‘Captagon’ logo 
have also increased recently, especially in Turkey where 
more than 15 million tablets were seized in 2015.
The Czech Republic, and more recently, the border areas of 
neighbouring countries, has long been the source of much 
of Europe’s methamphetamine. The drug is also produced 
in Bulgaria, Lithuania and the Netherlands.
In the Czech Republic, methamphetamine is produced 
mainly from the precursors ephedrine and 
pseudoephedrine, which are extracted from medicinal 
products smuggled chiefly from Poland. The drug may also 
be produced using BMK. In 2015, of the 291 illegal 
methamphetamine laboratories reported in the European 
Union, 263 were located in the Czech Republic. Production 
in that country has shifted from small-scale operations, 
involving users making quantities for personal use or local 
supply, to a situation dominated by larger-scale 
production, by organised crime groups, producing the drug 
for both consumption in European countries and export.
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FIGURE 1.7
Number of amphetamine seizures and quantity seized: trends and 2015 or most recent year
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FIGURE 1.8
Number of methamphetamine seizures and quantity seized: trends and 2015 or most recent year
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In 2015, 34 000 seizures of amphetamine were reported 
by EU Member States, amounting to 4.7 tonnes. Overall, 
the quantity of amphetamine seized in the European Union 
has increased, fluctuating between 4 and 6 tonnes over 
the period 2002 to 2015 (Figure 1.7). Methamphetamine 
seizures are far lower, with 7 700 seizures reported in the 
European Union in 2015, amounting to 0.5 tonne, with the 
Czech Republic seizing the largest amount (Figure 1.8). In 
2015, large quantities of amphetamines were also seized 
in Turkey (3.8 tonnes amphetamine and 0.3 tonne 
methamphetamine) and Norway (0.1 tonne 
methamphetamine). The number of seizures and quantity 
of methamphetamine seized show an upward trend 
since 2002.
Typically, the average reported purity is higher for 
methamphetamine than for amphetamine samples. 
Indexed trends suggest that amphetamine purity has 
increased in recent years.
 l MDMA: high-strength products available
MDMA (3,4-methylenedioxymethamphetamine) is a 
synthetic drug chemically related to amphetamines, but 
with different effects. MDMA is consumed as tablets (often 
called ecstasy), and powder and crystalline forms of the 
drug are also available. New MDMA tablet designs, in 
various colours, shapes and brand logos, are constantly 
being introduced into the market. After a period of low 
availability linked to a lack of precursor chemicals needed 
for its manufacture, the MDMA market has seen a revival in 
recent years. The retail MDMA market is estimated to be 
worth about EUR 0.7 billion. The average content of MDMA 
in tablets has increased in recent years, and high amounts 
of MDMA in some batches have been linked with harms 
and deaths.
Production of MDMA in Europe appears to be concentrated 
in Belgium and the Netherlands, with 4 MDMA laboratories 
dismantled in the European Union in 2015 (3 in the 
Netherlands, 1 in Belgium). MDMA produced in Europe is 
also exported to other parts of the world.
Assessing recent trends in MDMA seizures is difficult due 
to the absence of data from some countries that are likely 
to make important contributions to this total. For 2015, no 
data are available from the Netherlands, which reported 
MDMA seizures of 2.4 million tablets in 2012, and the 
numbers of seizures are not available from Poland and 
Finland. Without these important contributions, the 
quantity of MDMA seized in the European Union in 2015 is 
estimated at 4 million tablets and 0.2 tonnes of MDMA 
powder.
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 l New psychoactive substances: many and diverse
By the end of 2016, the EMCDDA was monitoring more 
than 620 new psychoactive substances that have 
appeared on Europe’s drug market. These substances are 
not covered by international drug controls and make up a 
broad range of drugs such as synthetic cannabinoids, 
stimulants, opioids and benzodiazepines (Figure 1.10). In 
most cases they are marketed as ‘legal’ replacements for 
illicit drugs, while others are aimed at small groups who 
wish to explore them for possible novel effects.
In many cases, new substances are produced in bulk 
quantities by chemical and pharmaceutical companies in 
China. From there they are shipped to Europe, where they 
are processed into products, packaged and sold. In 
addition, some new substances may be sourced as 
medicines, which are either diverted from the legitimate 
supply chain or sourced illegally. The substances may also 
be produced in clandestine laboratories, either in Europe 
or elsewhere. Various indicators, including detections of 
illicit laboratories, analysis of dumped synthetic drug 
waste and precursor seizures, suggest an increase in this 
form of production in the last few years in Europe.
The overall number of reported MDMA seizures has 
continued to rise since 2010, while the quantity seized has 
been relatively stable over the same period. Large 
quantities of MDMA were also seized in Turkey in 2015, 
amounting to 5.7 million tablets, more than the quantity 
reported by all other countries combined (Figure 1.9).
 l Seizures of LSD, GHB and ketamine
Seizures of other illicit drugs are reported in the European 
Union, including around 1 400 seizures of LSD (lysergic 
acid diethylamide) in 2015, amounting to 100 000 units. In 
addition, Belgium seized 1 kilogram of the drug. The overall 
number of LSD seizures has doubled since 2010, although 
the quantity seized has been fluctuating. In 2015, seizures 
of GHB (gamma-hydroxybutyrate) or GBL (gamma-
butyrolactone) were reported by 14 countries. The 
estimated 1 300 seizures amounted to 320 kilograms and 
over 1 500 litres of the drug, with Belgium (33 %) and 
Norway (35 %) together accounting for two thirds of these 
seizures. Twelve countries reported around 1 200 seizures 
of ketamine, amounting to an estimated 130 kilograms of 
the drug, most of which was accounted for by Denmark, 
Italy and the United Kingdom.
FIGURE 1.9
Number of MDMA seizures and quantity seized: trends and 2015 or most recent year
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The number of new substances detected each year is just 
one of a range of metrics that the EMCDDA uses in order 
to understand the overall market. For example, of the 620 
new substances currently being monitored, 423 (almost 
70 %) were detected on the drug market during 2015; this 
compares with 365 in 2014 and 299 in 2013 — illustrating 
how complex this market has become.
Some new substances are sold openly on the surface web 
and in specialised physical shops — often as branded 
‘legal high’ products. In addition, they are sold on darknet 
markets and on the illicit market, sometimes under their 
own name and sometimes falsely as illicit drugs such as 
heroin, cocaine, ecstasy and benzodiazepines.
More than 70 % of new substances that were detected 
through the European Union Early Warning System have 
been made in the last 5 years. During 2016, 66 new 
substances were detected for the first time in Europe. This 
is fewer than in either of the previous 2 years but is similar 
to the numbers detected in 2012 and 2013. The causes of 
this decrease are unclear, but may in part be due to 
measures taken by national governments in Europe to 
prohibit new substances, particularly their open sale as 
‘legal highs’. In addition, control measures and law 
enforcement operations in China targeting laboratories 
producing new substances may be another factor. Growing 
links with the broader illicit drug market may also be 
important.
FIGURE 1.10
Number and categories of new psychoactive substances notified 
to the EU Early Warning System for the first time, 2005–16
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 l New synthetic opioids
Overall, 25 new opioids have been detected on Europe’s 
drug market since 2009 — including 9 reported for the first 
time in 2016. This includes 18 fentanyls, 8 of which were 
reported for the first time in 2016. Although currently 
playing a small role in Europe’s drug market, the new 
fentanyls are highly potent substances that pose a serious 
threat to individual and public health.
New opioids have been seized in various forms: mainly 
powders, tablets, capsules, and since 2014, also as liquids. 
Over 60 % of the 600 seizures of new synthetic opioids 
reported in 2015 were fentanyls. Almost 2 litres of 
synthetic opioids was seized in 2015, an increase from the 
240 ml reported the previous year. Fentanyls were found in 
85 % of the liquids seized. One concern in this respect is 
the appearance on the market of nasal sprays containing 
fentanyls such as acryloylfentanyl and furanylfentanyl. 
Reflecting their low share of the market as well as their 
high potency, these opioids account for 0.75 % of the total 
number of seizures of new substances but for only 0.04 % 
of the total quantity seized.
 l Increase in seizures of new psychoactive substances
In 2015, almost 80 000 seizures of new psychoactive 
substances were reported through the EU Early Warning 
System. Together, the synthetic cathinones and synthetic 
cannabinoids accounted for over 60 % of all seizures of 
new substances in 2015 (over 47 000). Increases were 
also observed in the quantities seized in 2015, compared 
with the previous year, for synthetic cathinones, synthetic 
cannabinoids and new opioids.
European seizure totals for new substances must be 
understood as minimum values, as data are drawn from 
case reports rather than monitoring systems. Reported 
seizures are influenced by a range of factors such as 
increasing awareness of new substances, their changing 
legal status, law enforcement capacities and priorities, and 
the reporting practices of law enforcement agencies.
FIGURE 1.11
Number of seizures of new psychoactive substances reported to the EU Early Warning System: trends and distribution by category in 2015 
Number of seizure cases
NB: Data for EU Member States, Turkey and Norway.
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 l Synthetic cannabinoids
Synthetic cannabinoids are substances that mimic the 
effects of delta-9-tetrahydrocannabinol (THC), which is 
largely responsible for the major psychoactive effects of 
cannabis. Since at least 2008, producers in Europe have 
exploited this effect by importing bulk powders of the 
cannabinoids and mixing them with dried plant material in 
order to create hundreds of different ‘legal high’ products. 
These were then marketed as legal replacements for 
cannabis and sold as ready-to-use ‘herbal smoking 
mixtures’. Synthetic cannabinoids continue to be the 
largest group of new substances monitored by the 
EMCDDA and are becoming increasingly chemically 
diverse, with 169 detected since 2008 — including 11 
reported in 2016, a decrease from the 24 reported in 2015.
In 2015, just over 22 000 seizures of synthetic 
cannabinoids were reported (Figure 1.12). The five most 
commonly seized synthetic cannabinoids in 2015 were 
ADB-FUBINACA, AB-CHMINACA, UR-144, 5F-AKB48 and 
ADB-CHMINACA.
These seizures amounted to more than 2.5 tonnes of the 
substances. Almost two thirds (64 %) of the synthetic 
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FIGURE 1.12
Seizures of synthetic cannabinoids and cathinones reported to the EU Early Warning System: trends in number of seizures and quantity seized 
cannabinoid seizures were in the form of herbal mixtures, 
with powders accounting for 13 %.
The detection of synthetic cannabinoids in powder form 
and of processing facilities in Europe indicates that 
products are packaged in Europe. These powders, when 
processed into ‘herbal smoking mixtures’, could have been 
capable of producing many millions of doses. The most 
commonly seized cannabinoids in powder form in 2015 
were 5F-AMB (61 kg), 5F-AKB48 (61 kg) and ADB-
FUBINACA (57 kg).
 l Synthetic cathinones
Synthetic cathinones are chemically related to cathinone, 
which is a naturally occurring stimulant found in the khat 
plant (Catha edulis). These substances have effects similar 
to common illicit stimulant drugs such as amphetamine, 
cocaine and MDMA. Synthetic cathinones are the second 
largest group of new drugs monitored by the EMCDDA, 
with 118 detected in total — including 14 detected for the 
first time in 2016, a decrease from the 26 reported in 
2015.
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Synthetic cathinones were the most frequently seized new 
psychoactive substances in 2015, with over 25 000 
seizures, accounting for one third of the total number of 
seizures. This represents an increase of over 17 000 
seizures on the previous year. These seizures amounted to 
just over 1.8 tonnes, an increase of approximately 
0.75 tonne compared with 2014 (Figure 1.12). Synthetic 
cathinones are generally found in powder form. The five 
most commonly seized cathinones in 2015 were alpha-
PVP, 3-MMC, ethylone, 4-CMC and pentedrone. Where 
reported, more than 60 % (1.2 tonnes) of the synthetic 
cathinones seized in 2015 were shipped from China. A 
large share (42 %) of the synthetic cathinones seized were 
2-MMC (156 kg) and 3-MMC (616 kg), which are 
chemically related to mephedrone (4-MMC), but are not 
under international drug control. Mephedrone has become 
established in the illicit drug market in some countries, and 
it is likely that some of the 2-MMC and 3-MMC is being 
sold as mephedrone (see Figure 1.13).
 l New benzodiazepines
Also of concern is the recent growth in the market for new 
benzodiazepines. Some 20 of these substances are being 
monitored by the EMCDDA — 6 of which were detected for 
the first time in Europe in 2016. During 2015, more than 
300 000 tablets containing new benzodiazepines such as 
clonazolam, diclazepam, etizolam and flubromazolam 
were seized — almost twice the number reported in 2014. 
Some new benzodiazepines were sold as tablets, capsules 
or powders under their own names. In other cases, 
counterfeiters used these substances to produce fake 
versions of commonly prescribed anti-anxiety medicines, 
such as diazepam and alprazolam, which were sold 
directly on the illicit drug market.
 l Laws targeting supply of new psychoactive substances
European countries take measures to prevent the supply of 
drugs under three United Nations Conventions, which 
provide a framework for control of production, trade and 
possession of over 240 psychoactive substances. The 
rapid emergence of new psychoactive substances and the 
diversity of available products has proved challenging for 
the Conventions and for European policymakers and 
lawmakers.
At national level, various measures have been used to 
control new substances, and three broad types of legal 
response can be identified. Many countries in Europe first 
responded by using consumer safety legislation, and 
subsequently extended or adapted existing drug laws to 
incorporate new psychoactive substances. Increasingly, 
countries have designed specific new legislation to 
address this phenomenon. There is wide variation in the 
definitions of the offences and the penalties — as is the 
case for drug laws across Europe. The general trend in 
national drug control laws, that is to reduce penalties for 
personal possession, is also evident in recent laws on new 
drugs. Most of the new laws specific to new psychoactive 
substances only penalise illegal supply and have no 
penalty for personal possession.
FIGURE 1.13
Chemical formulas of 2-MMC, 3-MMC and mephedrone (4-MMC)
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At EU level, the current legal framework for the control of 
new psychoactive substances, which dated from 2005, is 
under revision, with the aim of establishing a swifter, more 
effective system for submitting conduct related to harmful 
new psychoactive substances to criminal law measures.
 l Drug supply penalties: vary by drug and country
Unauthorised drug supply is a crime in all European 
countries, but the penalties written in the law vary widely. A 
recent EMCDDA survey of the opinions of legal 
practitioners in EU Member States found that the penalties 
expected by these experts for similar drug trafficking 
offences varied considerably between countries (see 
Figure 1.14). These variations may be a result of national 
historical and cultural factors influencing a country’s 
criminal law systems, as well as different national views on 
the effectiveness of sentencing as a deterrent. The study 
also revealed that, although the legislation may contain 
similar penalties for different substances, in most 
countries the practitioners predicted that penalties would 
vary by substance. This would imply that judges take into 
account aspects such as perceived harm to society caused 
by the different drugs.
FIGURE 1.14
Expected prison sentence for supply of 1 kilogram of heroin or cannabis in EU Member States
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 l Drug law offences: majority related to cannabis
The implementation of laws is monitored through data on 
reported drug law offences. In the European Union, an 
estimated 1.5 million drug law offences were reported in 
2015, most of them (57 %) related to cannabis use or 
possession, involving around 1 million offenders. Reported 
offences increased by almost a third (31 %) between 2006 
and 2015.
Overall, reports of drug supply offences increased by 18 % 
since 2006, with an estimate of more than 214 000 cases 
in 2015. Cannabis accounted for the majority of supply 
offences (57 %). There has been a sharp increase in 
reports of supply offences for MDMA since 2013 
(Figure 1.15).
In Europe, overall, it is estimated that more than 1 million 
offences related to use or possession for personal use 
were reported in 2015, a 27 % increase compared with 
2006. Of the reported drug offences related to possession, 
about three quarters involve cannabis (74 %). The upward 
trends in offences for amphetamines and MDMA 
possession have continued in 2015 (Figure 1.15).
FIGURE 1.15
Drug law offences in Europe related to drug use or possession for use or drug supply: indexed trends and reported offences in 2015
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Drug use in Europe now encompasses 
a wider range of substances than in the 
past. Among drug users, polydrug 
consumption is common and individual 
patterns of use range from experimental 
to habitual and dependent 
consumption. Use of all drugs is 
generally higher among males, and this 
difference is often accentuated for more 
intensive or regular patterns of use. The 
prevalence of cannabis use is about five 
times that of other substances. While 
the use of heroin and other opioids 
remains relatively rare, these continue 
to be the drugs most commonly 
associated with the more harmful forms 
of use including injecting drug use.
Monitoring drug use
The EMCDDA collects and maintains datasets that 
cover drug use and patterns of use in Europe.
Surveys undertaken among school students and the 
general population can provide an overview of the 
prevalence of experimental and recreational drug 
use. These survey results can be complemented by 
community level analyses of drug residues in 
municipal wastewater, carried out in cities across 
Europe.
Studies reporting estimates of high-risk drug use can 
help to identify the extent of the more entrenched 
drug use problems, while data on those entering 
specialised drug treatment systems, when 
considered alongside other indicators, can inform 
understanding on the nature and trends in high-risk 
drug use.
Full data sets and methodological notes can be 
found in the online Statistical Bulletin.
Drug use prevalence 
and trends
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 l Diverse national substance use trends among school students
Monitoring substance use among students provides an 
important insight into current youth risk behaviours and 
potential future trends. In 2015, the European School 
Survey Project on Alcohol and Other Drugs (ESPAD) 
conducted the sixth round of data collection since its 
inception in 1995. The latest survey collected comparable 
data on substance use among 15- to 16-year-old students 
from 35 European countries, including 23 EU Member 
States and Norway. Among students in these 24 countries, 
on average, 18 % reported having used cannabis at least 
once (lifetime prevalence), with the highest levels reported 
by the Czech Republic (37 %) and France (31 %). Use of 
the drug in the last 30 days ranged from 2 % in Sweden, 
Finland and Norway to 17 % in France, with an average of 
8 % across the 24 countries. Gender differences varied 
across Europe, with the ratio of boys to girls among lifetime 
cannabis users ranging from parity in the Czech Republic 
and Malta to 2.5 boys to each girl in Norway.
SUBSTANCE USE AMONG 15- TO 16-YEAR-OLD EUROPEAN SCHOOL STUDENTS 
(2015 ESPAD)
Last month cannabis
use by gender
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NB: Based on data for the 23 EU Member States and Norway that participated in the 2015 round of ESPAD.
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The use of illicit drugs other than cannabis was far lower, 
with an overall lifetime prevalence of 5 %. The most 
frequently used illicit drugs after cannabis were MDMA/
ecstasy, amphetamine, cocaine, methamphetamine and 
LSD or other hallucinogens, each reported by 2 % of 
students. In addition, lifetime use of new psychoactive 
substances was reported by 4 % of students, with the 
highest rates in Estonia and Poland (10 % each).
Among the 22 countries with sufficient data for analysis 
(21 EU Member States and Norway), overall trends in last 
month cannabis prevalence peaked in 2003 and slightly 
decreased in subsequent surveys (Figure 2.1). Between 
the most recent surveys, 2011 and 2015, prevalence of 
both lifetime and last month cannabis use was stable for 
most of these countries. Since 1995, the lifetime 
prevalence of use of illicit drugs other than cannabis has 
remained largely unchanged, with a slight decrease 
between 2011 and 2015.
 Lifetime use of new  
 psychoactive substances  
 was reported by 4 %  
 of students 
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 l Recent decreases in tobacco use and heavy episodic drinking among school students
ESPAD also reports on the use of alcohol and tobacco. 
More than four fifths (83 %) of the students had consumed 
alcohol at least once in their lifetime. Half of the students 
reported drinking alcohol at least once in the last month, 
with 39 % of boys and 36 % of girls having had five or more 
drinks on one occasion during the last month (heavy 
episodic drinking).
Just under half (47 %) of students had smoked cigarettes. 
In the month prior to the survey, 23 % of students reported 
smoking one or more cigarette a day, with 3 % smoking 
more than 10 a day.
Among the 22 EMCDDA countries with sufficient data for 
trend analysis, an overall decrease in lifetime and last 
month use of both alcohol and cigarettes can be observed 
between 1995 and 2015. Changes in heavy episodic 
drinking were less pronounced, although an increase was 
observed for girls over the period. Between the 2011 and 
2015 surveys, there was a decrease in both heavy episodic 
drinking and last month cigarette use.
 l More than 93 million adults have tried illicit drugs
More than 93 million or just over a quarter of 15- to 
64-year-olds in the European Union are estimated to have 
tried illicit drugs during their lives. Experience of drug use 
is more frequently reported by males (56.8 million) than 
females (36.8 million). The most commonly tried drug is 
cannabis (53.8 million males and 34.1 million females), 
with much lower estimates reported for the lifetime use of 
cocaine (12.2 million males and 5.3 million females), 
MDMA (9.3 million males and 4.7 million females) and 
amphetamines (8.4 million males and 4.2 million females). 
Levels of lifetime use of cannabis differ considerably 
between countries, ranging from around 8 in 20 adults in 
France to less than 1 in 20 in Malta and Romania.
Last year drug use provides a measure of recent drug use 
and is largely concentrated among young adults. An 
estimated 18.7 million young adults (aged 15–34) used 
drugs in the last year, with twice as many males as 
females.
 l Cannabis use: varying national trends
Across all age groups, cannabis is the illicit drug most likely 
to be used. The drug is generally smoked and, in Europe, is 
commonly mixed with tobacco. Patterns of cannabis use 
can range from the occasional to the regular and 
dependent.
It is estimated that 87.7 million European adults (aged 
15–64), or 26.3 % of this age group, have experimented 
with cannabis at some time in their lives. Of these, an 
estimated 17.1 million young Europeans (aged 15–34), or 
13.9 % of this age group, used cannabis in the last year, 
with 10 million of these aged 15–24 (17.7 % of this age 
group). Last year prevalence rates among 15- to 34-year-
olds range from 3.3 % in Romania to 22 % in France. 
Among young people using cannabis in the last year, the 
ratio of males to females is two to one.
FIGURE 2.1
Trends in last month prevalence of heavy episodic drinking, 
cigarette use and cannabis use among 15- to 16-year-old European 
school students
NB: Based on the 21 EU Member States and Norway that have participated
in at least four rounds of ESPAD.
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FIGURE 2.2
Last year prevalence of cannabis use among young adults (15–34): 
most recent data (map) and selected trends 
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The most recent survey results show that countries 
continue to follow divergent paths in last year cannabis 
use. Of the countries that have produced surveys since 
2014 and reported confidence intervals, 7 reported higher 
estimates, 6 were stable and 2 reported lower estimates 
than in the previous comparable survey.
Few countries have sufficient survey data to permit 
statistical analysis of trends in last year use of cannabis 
among young adults (15–34). Among these, the long-term 
decreasing trends, previously observed over the last 
decade in Spain and the United Kingdom, have now 
stabilised in the more recent data (Figure 2.2).
In the last decade, an increasing trend can be seen in 
Ireland and Finland, and also in Sweden, though the 
prevalence in that country has been stable since 2009. 
In Germany, France and Denmark, no upward statistical 
trend is evident during this period, though the latest 
surveys point to recent increases in last year cannabis use 
among young adults. In 2014, France reported a new high 
of 22 %, while the 13 % reported in Germany in 2015 is the 
highest prevalence of last year cannabis use among young 
adults reported in that country in the last decade. Among 
countries lacking sufficient data for a statistical analysis of 
trends, in 2015, the second comparable annual survey 
from the Netherlands confirmed a prevalence of around 
16 %, while Austria’s first national survey since 2008 
reported a prevalence of 14 %.
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CANNABIS USERS ENTERING TREATMENT
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mean use 5.4 days per week
 l High-risk cannabis users: rising numbers entering treatment
Based on surveys of the general population, it is estimated 
that around 1 % of European adults are daily or almost 
daily cannabis users — that is, they have used the drug on 
20 days or more in the last month. Around 30 % of these 
are older drug users, aged 35 to 64, and over three 
quarters are male.
When considered alongside other indicators, data on those 
entering treatment for cannabis problems can provide 
information on the nature and scale of high-risk cannabis 
use in Europe. Overall, the number of first-time treatment 
entrants for cannabis problems increased from 43 000 in 
2006 to 76 000 in 2015. Multiple factors may lie behind 
this rise, including higher prevalence of cannabis use 
among the general population, increases in the number of 
intensive users, the availability of higher potency products, 
and increases in treatment referral and levels of provision.
 l Cocaine prevalence: stable national trends
Cocaine is the most commonly used illicit stimulant drug 
in Europe, and its use is more prevalent in southern and 
western countries. Among regular consumers, a broad 
distinction can be made between more socially integrated 
users, who often sniff powder cocaine (cocaine 
hydrochloride), and marginalised users, who inject cocaine 
or smoke crack (cocaine base), sometimes alongside the 
use of opioids.
It is estimated that 17.5 million European adults (aged 
15–64), or 5.2 % of this age group, have experimented 
with cocaine at some time in their lives. Among these are 
about 2.3 million young adults aged 15 to 34 (1.9 % of this 
age group) who have used the drug in the last year.
Only Ireland, Spain, the Netherlands and the United 
Kingdom report last year prevalence of cocaine use among 
young adults of 2.5 % or more. Across Europe, the 
decreases in cocaine use reported in previous years have 
not been observed in the most recent surveys. Of the 
countries that have produced surveys since 2014 and 
reported confidence intervals, 2 reported higher estimates, 
11 reported a stable trend, and 1 reported a lower estimate 
than in the previous comparable survey.
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
46
European Drug Report 2017: Trends and Developments
A statistical analysis of long-term trends in last year use of 
cocaine among young adults is only possible for a small 
number of countries, and new data confirm existing trends. 
Spain and the United Kingdom both reported trends of 
increasing prevalence until 2008, followed by stability or 
decline (Figure 2.3). While at lower levels of prevalence, an 
upward trend can be observed in France, with prevalence 
for the first time rising above 2 % in 2014. Statistically, the 
2015 survey in Germany showed a decline in cocaine 
prevalence, which had remained stable between 2000 and 
2009.
Analysis of municipal wastewater for cocaine residues 
carried out in a multi-city study complements the results 
from population surveys. Wastewater analysis reports on 
collective consumption of pure substances within a 
community, and the results are not directly comparable 
with prevalence estimates from national population 
surveys. The results of wastewater analysis are presented 
in standardised amounts (mass loads) of drug residue per 
1 000 population per day.
A 2016 analysis found the highest mass loads of 
benzoylecgonine — the main metabolite of cocaine — in 
cities in Belgium, Spain and the United Kingdom and very 
low levels in the majority of eastern European cities (see 
Figure 2.4). Of the 33 cities that have data for 2015 and 
2016, 22 reported an increase, 4 a decrease and 7 a stable 
situation. Stable or increasing longer-term trends are 
reported for most of the 13 cities with data for 2011 and 
2016.
 l High-risk cocaine use: stable treatment demand
The prevalence of high-risk cocaine use in Europe is 
difficult to gauge as only 4 countries have recent estimates 
and different definitions and methodologies have been 
used. In 2015, based on severity of dependence scale 
questions, Germany estimated high-risk cocaine use 
among the adult population at 0.20 %, while Spain used 
frequency of use to estimate high-risk cocaine use at 
0.24 %. In 2015, Italy produced an estimate of 0.65 % for 
those in need of treatment for cocaine use. High-risk 
cocaine use in Portugal was estimated at 0.62 % in 2012, 
based on reported last year use.
Spain, Italy and the United Kingdom account for three 
quarters (74 %) of all reported treatment entries related to 
cocaine in Europe. Overall, cocaine was cited as the 
primary drug by around 63 000 clients entering specialised 
drug treatment in 2015 and by around 28 000 first-time 
clients. After a period of decline, the overall number of 
cocaine first-time treatment entrants has been relatively 
stable since 2012.
In 2015, 7 400 clients entering treatment in Europe 
reported primary crack cocaine use, with the United 
Kingdom accounting for almost two thirds (4 800). Spain, 
France and the Netherlands together (1 900) account for 
most of the remainder.
FIGURE 2.3
Last year prevalence of cocaine use among young adults (15–34): selected trends and most recent data
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In addition, the United Kingdom (England) estimated crack 
cocaine use among the adult population at 0.48 % during 
2011/12. The majority of these crack users were also using 
opioids.
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FIGURE 2.4
Cocaine residues in wastewater in selected European cities: trends and most recent data
NB: Mean daily amounts of benzoylecgonine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in 2016.
Source: Sewage Analysis Core Group Europe (SCORE).
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 l MDMA: use continues to increase
MDMA (3,4-methylenedioxy-methamphetamine) is used in 
the form of tablets (often called ecstasy), and also in the 
form of crystals and powders; tablets are usually 
swallowed, but crystals and powder are taken orally and 
can also be ‘dabbed’ or snorted. Most European surveys 
have historically collected data on ecstasy rather than 
MDMA use, although this is now changing.
It is estimated that 14 million European adults (aged 
15–64), or 4.2 % of this age group, have experimented 
with MDMA/ecstasy at some time in their lives. Figures for 
more recent use, among the age group in which drug use 
is highest, suggest that 2.3 million young adults (15–34) 
used MDMA in the last year (1.8 % of this age group), with 
national estimates ranging from 0.3 % in Cyprus, Lithuania 
and Romania to 6.6 % in the Netherlands.
Until recently, in many countries, MDMA prevalence had 
been on the decline from peak levels attained in the early 
to mid-2000s. In recent years, however, monitoring sources 
indicate increased use of MDMA. Among the countries that 
have produced new surveys since 2014 and reported 
confidence intervals, results suggest a continued 
increasing trend in Europe, with 5 countries reporting 
higher estimates than in the previous comparable survey 
and 9 reporting stable estimates.
Where data exist for a statistical analysis of trends in last 
year use of MDMA among young adults, the more recent 
data suggest changes. Following stability or gradual 
increase since 2000, France and Finland report large 
increases in 2014 (Figure 2.5). In the United Kingdom, the 
increase observable since 2012 has been reduced by the 
2015 data, while in Spain, the long-term trend remains 
downward, although recent values are stable.
FIGURE 2.5
Last year prevalence of MDMA use among young adults (15–34): selected trends and most recent data 
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A 2016 multi-city analysis found the highest mass loads of 
MDMA in the wastewater in cities in Belgium, the 
Netherlands and Norway (Figure 2.6). Of the 32 cities that 
have data for 2015 and 2016, 17 reported an increase, 11 
reported a decrease and 4 a stable situation. Looking at 
longer-term trends, in most cities with data for both years, 
wastewater MDMA loads were higher in 2016 than in 
2011, with sharp increases observed in some cities.
MDMA is often taken alongside other substances, 
including alcohol, and has historically been closely linked 
with nightlife settings and especially with electronic dance 
music. Current indications suggest that, in higher-
prevalence countries, MDMA is no longer a niche or 
subcultural drug limited to dance clubs and parties, but is 
used by a broad range of young people in mainstream 
nightlife settings, including bars and house parties.
MDMA use is rarely cited as a reason for entering 
specialised drug treatment. In 2015, MDMA was reported 
by less than 1 % (around 900 cases) of first-time treatment 
entrants in Europe.
FIGURE 2.6
MDMA residues in wastewater in selected European cities: trends and most recent data
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 l Amphetamines use: divergent national situations
Amphetamine and methamphetamine, two closely related 
stimulants, are both consumed in Europe, although 
amphetamine is much more commonly used. 
Methamphetamine consumption has historically been 
restricted to the Czech Republic and, more recently, 
Slovakia, although recent years have seen increases in use 
in other countries. In some data sets, it is not possible to 
distinguish between these two substances; in these cases, 
the generic term amphetamines is used.
Both drugs can be taken orally or nasally; in addition, 
injection is common among high-risk users in some 
countries. Methamphetamine can also be smoked, but this 
route of administration is not commonly reported in 
Europe.
It is estimated that 12.5 million European adults (aged 
15–64), or 3.8 % of this age group, have experimented 
with amphetamines at some time in their lives. Figures for 
more recent use, among the age group in which drug use 
is highest, suggest that 1.3 million (1.1 %) young adults 
(aged 15–34) used amphetamines during the last year, 
with the most recent national prevalence estimates 
ranging from 0.1 % in Cyprus, Portugal and Romania to 
3.1 % in the Netherlands. The available data suggest that 
since around 2000, most European countries have 
experienced a relatively stable situation in respect to 
trends in use. Of the countries that have produced new 
surveys since 2014 and reported confidence intervals, 2 
reported higher estimates, 10 reported a stable trend and 
2 reported lower estimates than in the previous 
comparable survey.
A statistical analysis of trends in last year prevalence of 
amphetamines in young adults is only possible in a small 
number of countries. In Spain, Latvia and the United 
Kingdom long-term downward trends are observable 
(Figure 2.7). In contrast, Finland has seen prevalence 
increases since 2000.
Analysis of municipal wastewater carried out in 2016 
found that mass loads of amphetamine varied 
considerably across Europe, with the highest levels 
reported in cities in the north of Europe (see Figure 2.8). 
Amphetamine was found at much lower levels in cities in 
the south of Europe. Of the 32 cities that have data for 
2015 and 2016, 13 reported an increase, 9 a stable 
situation and 10 a decrease. Overall, the data from 2011 to 
2016 showed relatively stable trends for amphetamine.
Methamphetamine use, generally low and historically 
concentrated in the Czech Republic and Slovakia, now 
appears to be present also in the east of Germany and 
northern Europe, particularly in cities in Finland (see 
Figure 2.9). In 2015 and 2016, of the 30 cities that have 
data on methamphetamine in wastewater, 13 reported an 
increase, 10 a stable situation and 7 a decrease.
FIGURE 2.7
Last year prevalence of amphetamines use among young adults (15–34): selected trends and most recent data 
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FIGURE 2.8
FIGURE 2.9
Amphetamine residues in wastewater in selected European cities: trends and most recent data
Methamphetamine residues in wastewater in selected European cities: trends and most recent data
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 l High-risk amphetamines use: rising treatment demand
Problems related to long-term, chronic and injecting 
amphetamine use have, historically, been most evident in 
northern European countries. In contrast, long-term 
methamphetamine problems have been most apparent in 
the Czech Republic and Slovakia. Recent estimates of 
high-risk use of amphetamines are available for Norway, 
estimated at 0.33 % or 11 200 adults and for Germany, 
estimated at 0.19 % or 102 000 users in 2015. Users of 
amphetamines are likely to make up the majority of the 
estimated 2 180 (0.17 %) high-risk stimulant users 
reported by Latvia in 2014, down from 6 540 (0.46 %) in 
2010. Recent estimates of high-risk methamphetamine 
use are available for the Czech Republic and Cyprus. In the 
Czech Republic, high-risk methamphetamine use among 
adults (15–64) was estimated at around 0.49 % in 2015. 
High-risk use of the drug, mainly injecting, increased from 
20 900 users in 2007 to a peak of 36 400 in 2014, 
declining to 34 200 in 2015. The estimate for Cyprus is 
0.14 % or 678 users in 2015.
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Approximately 34 000 clients entering specialised drug 
treatment in Europe in 2015 reported amphetamines as 
their primary drug, of whom around 14 000 were first-time 
clients. Primary amphetamine users account for more than 
15 % of first-time treatment entrants only in Bulgaria, 
Germany, Latvia, Poland and Finland. Treatment entrants 
reporting primary methamphetamine use are concentrated 
in the Czech Republic and Slovakia, which together 
account for 90 % of the 9 000 methamphetamine clients in 
specialised treatment in Europe. Overall, the increasing 
trend in first-time treatment entrants reporting 
amphetamine or methamphetamine as their primary drug, 
observed from 2006 until 2014, continued in 2015 in most 
countries.
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 l Ketamine, GHB and hallucinogens: use remains low
A number of other substances with hallucinogenic, 
anaesthetic, dissociative or depressant properties are used 
in Europe: these include LSD (lysergic acid diethylamide), 
hallucinogenic mushrooms, ketamine and GHB (gamma-
hydroxybutyrate).
The recreational use of ketamine and GHB (including its 
precursor GBL, gamma-butyrolactone) has been reported 
among subgroups of drug users in Europe for the last two 
decades. National estimates, where they exist, of the 
prevalence of GHB and ketamine use in adult and school 
populations remain low. In their 2015 survey, Norway 
reported last year prevalence of GHB use at 0.1 % for 
adults (16–64). In 2015, last year prevalence of ketamine, 
poppers and GHB use among young adults (15–34) was 
estimated at 0.6 % in the Czech Republic and the United 
Kingdom.
The overall prevalence levels of LSD and hallucinogenic 
mushroom use in Europe have been generally low and 
stable for a number of years. Among young adults (15–34), 
national surveys report last year prevalence estimates of 
less than 1 % for both substances, with the exception of 
the Netherlands (1.1 %) and the Czech Republic (2.2 %) for 
hallucinogenic mushrooms in 2015, and Finland with a 
prevalence of 1.3 % for LSD in 2014.
 l New psychoactive substance use: low in the general population
A number of countries have included new psychoactive 
substances in their general population surveys, although 
different methods and survey questions limit comparisons 
between countries. Since 2011, 11 European countries 
have reported national estimates of the use of new 
psychoactive substances (not including ketamine and 
GHB). For young adults (aged 15–34), last year prevalence 
of use of these substances ranges from 0.3 % in Austria, to 
1.6 % in the Czech Republic and Ireland.
Survey data on the use of mephedrone are available for the 
United Kingdom (England and Wales). In the most recent 
survey (2015/16), last year use of this drug among 16- to 
34-year-olds was estimated at 0.5 %; down from 1.1 % in 
2014/15.
A small number of surveys include questions on the use of 
synthetic cannabinoids. Last year use of synthetic 
cannabinoids among 15- to 34-year-olds was estimated at 
1.5 % in Latvia and 0.4 % in Slovakia in 2015 and at 0.1 % 
in Finland in 2014. Also in 2014, an estimated 4 % of 18- 
to 34-year-olds in France reported having ever used 
synthetic cannabinoids.
 l New psychoactive substances: high-risk use in marginalised populations
The use of new psychoactive substances by high-risk drug 
users was explored by the EMCDDA in 2016. The study 
found that while consumption levels were low overall in 
Europe, patterns of use were linked to multiple problems. A 
majority of European countries (22) reported some level of 
use of new psychoactive substances among high-risk user 
groups, although more extensive use among opioid and 
stimulant injectors was limited to Hungary and parts of the 
United Kingdom. The injection of synthetic cathinones was 
reported in half (15) of countries, with the substance used 
often varying by country; for example, mephedrone in the 
United Kingdom, alpha-PVP in Finland, pentedrone in 
Hungary and 3-MMC in Slovenia. The smoking of synthetic 
cannabinoids in marginalised populations, including 
among homeless people and prisoners, is an emerging 
problem identified in around two thirds of European 
countries.
Few people currently enter treatment in Europe for 
problems associated with use of new psychoactive 
substances, although under-reporting in this area is likely. 
In 2015, around 3 200 clients, or less than 1 % of those 
entering specialised drug treatment in Europe, reported 
problems related to these substances. In the United 
Kingdom, around 1 500 treatment entrants (or around 1 % 
of all drug clients) reported primary use of synthetic 
cathinones; Hungary and Romania also report relatively 
high numbers of new psychoactive substance users 
entering drug treatment.
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 l High-risk opioid users: heroin still dominates
In Europe, the most commonly used illicit opioid is heroin, 
which may be smoked, snorted or injected. A range of 
synthetic opioids such as methadone, buprenorphine and 
fentanyl are also misused.
Europe has experienced different waves of heroin 
addiction, the first affecting many western countries from 
the mid-1970s and a second wave affecting other 
countries, especially those in central and eastern Europe, 
in the mid to late 1990s. In recent years, the existence of 
an ageing cohort of high-risk opioid users, who are likely to 
have been in contact with substitution treatment services, 
has been identified.
The average prevalence of high-risk opioid use among 
adults (15–64) is estimated at 0.4 % of the EU population, 
the equivalent of 1.3 million high-risk opioid users in 
Europe in 2015. At national level, prevalence estimates of 
high-risk opioid use range from less than 1 to more than 8 
cases per 1 000 population aged 15–64 (Figure 2.10). Five 
countries account for three quarters (76 %) of the 
estimated high-risk opioid users in the European Union 
(Germany, Spain, France, Italy, United Kingdom). Of the 10 
countries with multiple estimates of high-risk opioid use 
between 2007 and 2015, Spain shows a statistically 
significant decrease (Figure 2.10).
In 2015, 191 000 clients who entered specialised 
treatment in Europe reported opioids as their primary drug, 
37 000 of whom were first-time entrants. Primary heroin 
users accounted for 79 % of first-time primary opioid users 
entering treatment.
 l An ageing population of opioid users
The number of first-time heroin clients more than halved 
from a peak of 56 000 in 2007, to 23 000 in 2013 before 
increasing to 29 000 in 2015. The recent increase can be 
seen in several countries, but it needs to be interpreted 
with caution, as changes in national reporting may have 
had an impact on the EU total.
Many long-term opioid users in Europe, typically with 
polydrug use histories, are now aged in their 40s and 50s. 
Between 2006 and 2015, the mean age of those entering 
treatment for problems related to opioid use increased by 
4 years (see Figure 2.11). During the same period, the 
average age of drug-induced deaths (which are mainly 
related to opioids) increased by 5.5 years. A history of 
injecting drug use and poor health, bad living conditions 
and tobacco and alcohol use makes these users 
susceptible to a range of chronic health problems, 
including cardiovascular and lung problems. Long-term 
opioid users also report chronic pain conditions, while 
FIGURE 2.10
National estimates of annual prevalence rate of high-risk opioid use: selected trends and most recent data
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FIGURE 2.11
Treatment entrants with opioids as primary drug: shifts in the age structure over time (left) and mean age by country (right)
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chronic infection with the hepatitis C virus can place them 
at increased risk of cirrhosis and other liver problems. The 
cumulative effects of polydrug use, overdose and 
infections over many years accelerate physical ageing 
among these users, with considerable implications for 
treatment, social support services and prevention of 
drug-related deaths.
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 l Synthetic opioids: increasingly seen in high-risk opioid use
While heroin remains the most commonly used illicit 
opioid, a number of sources suggest that licit synthetic 
opioids (such as methadone, buprenorphine, fentanyl) are 
increasingly misused. In 2015, 17 European countries 
reported that more than 10 % of all opioid clients entering 
specialised services presented for problems primarily 
related to opioids other than heroin (Figure 2.12). Opioids 
reported by treatment entrants include methadone, 
buprenorphine, fentanyl, codeine, morphine, tramadol and 
oxycodone. In some countries, non-heroin opioids 
represent the most common form of opioid use among 
treatment entrants. In Estonia, the majority of treatment 
entrants reporting an opioid as their primary drug were 
using fentanyl, while buprenorphine is the most frequently 
misused opioid in Finland. In the Czech Republic, although 
heroin is the most common primary opioid, other opioids 
account for just over half of those entering treatment for 
opioid-related problems.
 l Injecting drug use: lowest levels ever among new treatment entrants
Injecting drug use is most commonly associated with 
opioids, although in a few countries, the injection of 
stimulants such as amphetamines or cocaine is a problem.
Only 12 countries have estimates of the prevalence of 
injecting drug use since 2012, where they range from less 
than 1 to 9 cases per 1 000 population aged 15–64.
Among first-time clients entering drug treatment in 2015 
with heroin as their primary drug, 29 % reported injecting 
as their main route of administration, down from 43 % in 
2006 (Figure 2.13). In this group, levels of injecting vary 
between countries, from 8 % in Spain to 90 % or more in 
Latvia, Lithuania and Romania. Injecting is reported as the 
main route of administration by 46 % of first-time primary 
amphetamines clients — a small increase since 2006 
— and by 1 % of first-time cocaine clients. Taking the main 
three injected drugs together, among first-time entrants to 
treatment in Europe, injecting as the main route of 
administration has declined from 28 % in 2006 to 19 % 
in 2015.
FIGURE 2.12
Treatment entrants citing opioids as primary drug: by type of opioid (left) and percentage reporting opioids other than heroin (right)
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The injection of synthetic cathinones, although not a 
widespread phenomenon, continues to be reported in 
specific populations, including opioid injectors and drug 
treatment clients in some countries. In a recent EMCDDA 
study, 10 countries reported synthetic cathinone injection 
(often with other stimulants and GHB) in the context of sex 
parties among small groups of men who have sex with 
men.
FIGURE 2.13
Trends in first-time treatment entrants reporting injecting 
as the main route of administration of their primary drug 
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Chapter 3
Illicit drug use is a recognised 
contributor to the global burden of 
disease. Chronic and acute health 
problems are associated with the use of 
illicit drugs, and these are compounded 
by various factors including properties 
of the substances, the route of 
administration, individual vulnerability 
and the social context in which drugs 
are consumed. Chronic problems 
include dependence and drug-related 
infectious disease, while there is a 
range of acute harms, with drug 
overdose the best documented of 
these. Although relatively rare, the use 
of opioids still accounts for much of the 
morbidity and mortality associated with 
drug use. Risks are elevated through 
injecting drug use. In comparison, 
although the health problems 
associated with cannabis use are 
clearly lower, the high prevalence of use 
of this drug may have implications for 
public health. The variation in content 
and purity of substances now available 
to users increases potential harms and 
creates a challenging environment for 
drug-related responses.
The design and delivery of effective evidenced-based 
responses to drug problems is a central focus for European 
drug policies and involves a range of measures. Prevention 
and early intervention approaches aim to prevent drug use 
and related problems, while treatment, including both 
psychosocial and pharmacological approaches, represents 
the primary response to dependence. Some core 
interventions, such as opioid substitution treatment and 
needle and syringe programmes, were developed in part as 
a response to injecting opioid use and related problems, 
particularly the spread of infectious diseases and overdose 
deaths.
Monitoring drug-related harms and responses
Information on health and social responses to drug 
use, including drug strategies and drug-related 
public expenditure, are provided to the EMCDDA by 
Reitox national focal points and expert working 
groups. Expert ratings provide supplementary 
information on the availability of interventions where 
more formalised datasets are unavailable. This 
chapter is also informed by reviews of the scientific 
evidence on the effectiveness of public health 
interventions. Supporting information can be found 
on the EMCDDA website in the Health and social 
responses profiles and the Best practice portal.
Drug-related infectious diseases and mortality and 
morbidity associated with drug use are the principal 
health harms monitored systematically by the 
EMCDDA. These are complemented by more limited 
data on acute drug-related hospital presentations 
and data from the EU Early Warning System, which 
monitors harms associated with new psychoactive 
substances. Further information is available online 
under Key epidemiological indicators, the Statistical 
Bulletin and Action on new drugs.
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 l Drug strategies: coordinating responses
National drug strategies are planning and coordination 
tools commonly used by European countries to set out 
their responses to the various health, social and security 
challenges linked to drug problems. They usually include 
some general principles, objectives and priorities, while 
also specifying actions and those responsible for 
implementation. While Denmark has a national drug policy 
that is expressed in a range of strategic documents, 
legislation and concrete actions, all other countries have a 
national drug strategy document. In 18 countries, the drug 
strategy is focused mainly on illicit drugs. In the other 12 
countries, the policy focus is broader, giving greater 
consideration to other addictive substances and 
behaviours. However, within the United Kingdom, the 
devolved administrations of Wales and Northern Ireland 
have broad strategy documents. When these two 
documents are included, the total number of broad illicit 
drug strategies increases to 14 (see Figure 3.1). These 
broad documents mainly address illicit drugs, and there is 
variation in how other substances and addictions are 
considered. All 14 documents address alcohol, 9 consider 
tobacco, 8 cover medicines, 3 include doping in sports 
(e.g. performance enhancing drugs) and 7 look at addictive 
behaviours (e.g. gambling). National drug strategies 
support the balanced approach to drug policy put forward 
in the EU drug strategy (2013–2020) and action plans 
(2013–2016 and 2017–2020), which place equal 
emphasis on drug demand reduction and drug supply 
reduction.
Evaluating a national drug strategy is now a standard 
practice among the EU Member States. Evaluations 
generally aim to assess the level of strategy 
implementation achieved and changes in the overall drug 
situation over time. In 2016, 10 multi-criteria evaluations, 
10 implementation progress reviews and 4 issue-specific 
evaluations were reported as having recently taken place, 
while 6 countries used other approaches such as a mix of 
indicator assessment and research projects. As some 
countries extend the scope of their drug strategies to 
include other substances and behavioural addictions, 
devising methods and indicators to monitor and evaluate 
these policy documents may become more challenging.
FIGURE 3.1
Focus of national drug strategy documents: illicit drugs or broader
Illicit drugs focus
Broader focus
NB: Strategies with broader focus may include, for example, licit drugs and
other addictions. While the United Kingdom has an illicit drug strategy, both
Wales and Northern Ireland have broad strategy documents which include
alcohol.
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 l Demand reduction: European standards
At European and national level, quality standards for drug 
demand reduction are increasingly recognised as a tool for 
the implementation of evidence-based interventions. In 
2015, the EU Council of Ministers adopted 16 minimum 
quality standards in drug demand reduction in the 
European Union, and countries have been encouraged to 
integrate them into their drug policies. The European 
quality standards are a set of aspirational statements for 
prevention, treatment, harm reduction and social 
reintegration. These standards link intervention quality to 
concrete measures, including appropriate staff training 
and provision of evidence-based interventions, and to 
principles such as respect for individual needs and 
adherence to ethics. They also highlight the need for the 
participation of all the stakeholders, including civil society, 
in the implementation and evaluation of interventions.
EMCDDA data collection reveals that quality standards 
currently exist in most European countries and others are 
in the process of developing them. Quality standards are 
being put into use in different ways. In some countries, 
standards are linked to service delivery and are used to 
evaluate the provision. They are also being used as a 
requirement for participation in competitions for service 
contracts and as instruments for service-level self-
assessment.
 l Delivering prevention: a systems approach
The prevention of drug use and drug-related problems 
among young people encompasses a wide range of 
approaches. Environmental and universal approaches 
target entire populations, selective prevention targets 
vulnerable groups who may be at greater risk of developing 
drug use problems, and indicated prevention focuses on 
at-risk individuals.
 Quality standards  
 currently exist in most  
 European countries 
 l Drug-related responses: the costs of actions
Understanding the costs of drug-related actions is an 
important aspect of policy evaluation. However, the 
information available on drug-related public expenditure in 
Europe, at both local and national level, remains sparse 
and heterogeneous. For the 23 countries that have 
produced estimates in the past 10 years, drug-related 
public expenditure is estimated at between 0.01 % and 
0.5 % of gross domestic product (GDP).
Spending on demand reduction as a share of the overall 
drug budget varied substantially across countries, 
representing between 23 % and 83 % of drug-related 
public expenditure. While differences are due in part to 
different policy options and the organisation of public 
services, the completeness of estimates also has a large 
impact. In current estimates, drug treatment and other 
health costs account for a large share of demand reduction 
expenditure. While the monitoring of expenditure on drug 
treatment remains the most developed to date, 
methodological improvements are still required.
Public spending on responses to the drug problem is only 
part of the cost borne by society in relation to illicit drugs. 
To this can be added the costs borne by the individual, 
such as private contributions to medical care, and external 
costs to society, such as losses of productivity and the 
financial costs due to premature deaths and illness linked 
to drug use. Assessment of these wider costs to society 
may allow resources to be more effectively targeted. In the 
European countries for which information is available, the 
social cost of illicit drugs is estimated to be between 0.1 % 
and 2 % of GDP.
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Many differences exist between European countries in the 
way prevention is addressed, with some tending to adopt 
broader community-based and environmental approaches 
(e.g. regulating alcohol and nightlife) and others primarily 
using manual-based programmes. The use of manual-
based prevention programmes, characterised by strictly 
defined content and delivery, can be an effective way to 
reach large populations with evidence-based interventions. 
Such programmes are reported as a central component in 
national prevention approaches in 6 Member States.
Other countries have prioritised a broader systems 
approach to their prevention interventions, focusing not 
just on individual programmes, but also on factors such as 
delivery mechanisms, interaction between interventions 
and the social and policy context. An example of this is the 
Communities That Care approach, which is being 
implemented in 5 EU countries. This approach, developed 
in the United States, is based on the premise that a 
reduction in the prevalence of health and behavioural 
problems among youth can be achieved by identifying risk 
and protective factors, and selecting effective early 
intervention programmes that address these. A recent 
systematic review found some positive evidence of 
effectiveness of the Communities That Care approach as a 
drug prevention initiative in US studies, although it has yet 
to be evaluated in the European context.
 l Addressing vulnerability and risk
Selective prevention responses for vulnerable groups are 
implemented in European countries through interventions 
that address both individual behaviours and social 
contexts. At the local level, such approaches can involve 
multiple services and stakeholders (e.g. social, family, 
youth and police), and are common in the Nordic countries 
and Ireland, as well as parts of Spain and Italy. The groups 
most frequently targeted are young offenders, pupils with 
academic and social problems and youth in care 
institutions. Little is known about the actual contents of 
these prevention strategies and evaluation is limited. 
Expert opinion data, however, indicates that the most 
commonly used selective prevention techniques are based 
on information provision.
Prevention approaches that target high-risk 
neighbourhoods have been implemented in some 
countries, utilising new methods such as the redesigning 
of urban spaces, and risk maps to help prioritise 
interventions. Provision for these types of interventions is 
reported to be highest in the north and west of Europe (see 
Figure 3.2), and approaches which have good evidence of 
effectiveness (normative and environmental) are 
implemented in just over a quarter of countries.
Indicated prevention targets at-risk individuals. Provision 
of this type of intervention is limited in Europe, with only 4 
countries reporting that indicated prevention programmes 
are available to the majority of those in need.
 l Brief interventions
Brief interventions aim to prevent or delay substance use, 
reduce its intensity or prevent escalation into problem use. 
These time-limited interventions operate in the grey area 
between prevention and treatment, and typically target 
young people or people at risk of substance use problems. 
They can be delivered by a variety of health and social 
professionals, including general practitioners, counsellors, 
youth workers and police officers, and often incorporate 
elements of motivational interviewing.
Current data indicate that brief interventions are not widely 
implemented in Europe, with 3 countries reporting full and 
extensive provision of such interventions in schools, and 2 
reporting that level of provision in low-threshold services.
Brief interventions have been characterised as relatively 
low-cost, with the potential for delivery in multiple settings 
by a variety of professionals after brief training. Examples 
of brief interventions implemented in several countries are 
eSBIRT, which provides brief interventions in emergency 
departments (Belgium), and Fred, which targets young 
people at an initial stage of criminal prosecution (Germany, 
Cyprus, Poland, Romania, Slovenia). However, a recent 
EMCDDA review found that while research supporting the 
effectiveness of brief interventions exists, it is still 
incomplete and more knowledge is needed on the extent 
of implementation.
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
65
Chapter 3 I Drug-related harms and responses
FIGURE 3.2
Prevention interventions targeting high-risk neighbourhoods implemented in European countries: evidence base and level of provision
Intervention Number of countries
approach 
Provision
NB: Based on expert ratings.
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 l Referral to treatment and length of stay
Drug treatment is the primary intervention utilised for 
individuals who experience problems with their drug use, 
including dependence, and ensuring good access to 
appropriate treatment services is a key policy aim. 
Monitoring treatment outcomes is important for improving 
the treatment journeys that clients take and adjusting 
services to better fit observed needs.
Self-referral continues to be the most common route into 
treatment. This form of referral, which also includes referral 
by family members or friends, accounted for around half of 
those entering specialised drug treatment in Europe in 
2015. An additional 25 % of clients were referred by health 
and social services, while 15 % were referred by the 
criminal justice system. In a number of countries, schemes 
are in place to divert drug offenders away from the criminal 
justice system and into drug treatment programmes. This 
may involve a court order to attend treatment or a 
suspended sentence conditional on treatment; in some 
countries diversion is also possible at earlier stages of the 
criminal justice process. In 2015, cannabis clients were the 
most likely to be referred by the criminal justice system; in 
Hungary, around 80 % of cannabis treatment referrals 
came from this source.
Client pathways through drug treatment are often 
characterised by the use of different services, multiple 
entries and varying lengths of stay. An insight into 
treatment journeys is provided by results from an analysis 
of specialised treatment data from 7 European countries in 
2015. Of the 400 000 clients reported in treatment in 
these countries during that year, just under 20 % had 
entered treatment for the first time in their life; around 
30 % had re-entered treatment, having received treatment 
in an earlier year; and around half had been in continuous 
treatment for more than 1 year. Most of the clients in 
continuous treatment were males, in their late 30s, had 
been in treatment for more than 3 years and had problems 
related to opioid use, especially heroin.
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 l Cannabis treatment: a range of approaches
Regular and long-term cannabis use is associated with 
increased risk of a number of physical and mental health 
problems including dependence. While many countries 
offer treatment for people with cannabis problems within 
generic substance use programmes, around half have 
developed some cannabis-specific treatment options. 
Services for cannabis users can be diverse, ranging from 
brief interventions delivered online, to longer-term 
therapeutic engagement in specialist centres. Although 
most treatment for this group takes place in community or 
outpatient settings, around one in five people entering 
specialist inpatient drug treatment services reported a 
primary cannabis-related problem.
Treatment for cannabis problems is based mainly on 
psychosocial approaches; family-based interventions are 
often used for adolescents and cognitive-behavioural 
interventions for adults. The available evidence supports 
the use of a combination of cognitive-behavioural therapy, 
motivational interviewing and contingency management 
approaches. In addition, there is some evidence to support 
the use of multidimensional family therapy for young 
cannabis users. Internet and digital-based interventions 
are increasingly employed to reach cannabis users, and 
studies to measure the effects of this type of interventions 
show promising preliminary results with regard to reducing 
levels of consumption and facilitating face to face 
treatment entry (when needed).
A number of studies are investigating the use of 
pharmacological interventions for cannabis-related 
problems. This includes looking at the potential for using 
THC, and synthetic THC, in combination with other 
psychoactive medicines, including antidepressants, 
anxiolytics and mood stabilisers. To date, results have 
been inconsistent, and no effective pharmacological 
approach to treat cannabis dependence has been 
identified.
 l Drug treatment: mainly provided in community settings
An estimated 1.4 million people received treatment for 
illicit drug use in the European Union during 2015 
(1.6 million including Norway and Turkey). Opioid users 
represent the largest group undergoing specialised 
treatment and consume the greatest share of available 
treatment resources, mainly in the form of substitution 
treatment. Cannabis and cocaine users are the second 
and third largest groups entering these services 
(Figure 3.3), with psychosocial interventions the main 
treatment modality for these clients. Differences between 
countries can be very large, however, with opioid users 
accounting for more than 90 % of treatment entrants in 
Estonia and less than 5 % in Hungary.
The majority of drug treatment in Europe is provided in 
outpatient settings, with specialised outpatient centres 
representing the largest provider in terms of number of 
drug users treated (Figure 3.4). General healthcare centres 
are the second largest providers. This category includes 
general practitioners’ surgeries, which are important 
prescribers of opioid substitution treatment in some large 
countries such as Germany and France. Elsewhere, for 
example in Slovenia, mental healthcare centres may play a 
key role in outpatient treatment provision.
 Services for cannabis  
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Trends in percentage of clients entering specialised drug treatment, 
by primary drug
Numbers receiving drug treatment in Europe in 2015, by setting
A smaller share of drug treatment in Europe is provided in 
inpatient settings, including hospital-based residential 
centres (e.g. psychiatric hospitals), therapeutic 
communities and specialised residential treatment 
centres. The relative importance of outpatient and 
inpatient provision within national treatment systems 
varies greatly between countries.
Increasingly, a wide range of drug treatment interventions 
are also provided online. Internet-based interventions have 
the potential to extend the reach and geographical 
coverage of treatment programmes to people experiencing 
drug use problems who may not otherwise access 
specialist drug services.
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 l Substitution treatment for opioid use problems
Substitution treatment, typically combined with 
psychosocial interventions, is the most common treatment 
for opioid dependence. The available evidence supports 
this approach, with positive outcomes found in respect to 
treatment retention, illicit opioid use, reported risk 
behaviour, drug-related harms and mortality.
An estimated 630 000 opioid users received substitution 
treatment in the European Union in 2015 (650 000 
including Norway and Turkey). The trend shows an increase 
in clients up to a peak in 2010, followed by a 6 % decline to 
2015. Between 2010 and 2015, decreases were observed 
in 12 countries, with the largest (decreases of more than 
25 %) reported by Spain, Hungary, the Netherlands and 
Portugal. This decline may be explained by factors related 
to demand or provision, including a falling population of 
ageing, chronic opioid users or shifts in treatment goals in 
some countries. Other countries have continued to expand 
provision, as they seek to improve treatment coverage, 
with 12 countries reporting increases between 2010 and 
2015, including Latvia (157 %), Finland (67 %) and Greece 
(61 %).
These two tendencies are confirmed in the most recent 
data (2014–15), with 12 countries reporting increases in 
the overall number of clients in substitution treatment and 
9 reporting decreases.
A comparison with current estimates of the number of 
high-risk opioid users in Europe would suggest that half 
receive substitution treatment, but there are differences 
between countries (Figure 3.5). However, these findings 
must be interpreted cautiously for methodological reasons.
Methadone is the most commonly prescribed opioid 
substitution drug, received by around two thirds (63 %) of 
substitution clients. A further 35 % of clients are treated 
with buprenorphine-based medications, which is the 
principal substitution drug in 8 countries (Figure 3.6). 
Other substances, such as slow-release morphine or 
diacetylmorphine (heroin), are more rarely prescribed, 
being received by an estimated 2 % of substitution clients 
in Europe.
 Methadone is the most  
 commonly prescribed  
 opioid substitution drug 
10
3
4
13Fr
an
ce
Po
rtu
ga
l
M
alt
a
Ne
th
er
lan
ds
Cr
oa
tia
Sl
ov
en
ia
Au
st
ria
Gr
ee
ce
Lu
xe
m
bo
ur
g
Ge
rm
an
y
No
rw
ay
UK
 (E
ng
lan
d)
Cz
ec
h 
Re
pu
bl
ic
Hu
ng
ar
y
Po
lan
d
Cy
pr
us
La
tv
ia
30
50
Percent
NB: Data displayed as point estimates and uncertainty intervals.
High (>50 %)
Medium (30–50 %)
Low (<30 %)
Coverage not calculable
Number of countries
per coverage level
100
90
80
70
60
40
20
10
0
FIGURE 3.5
Coverage of opioid substitution treatment (percentage of estimated high-risk opioid users receiving the intervention)
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Principal opioid substitution drug prescribed
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FIGURE 3.7
Percentage of high-risk opioid users receiving drug treatment 
(estimate)
Although less common than substitution treatment, 
alternative treatment options for opioid users are available 
in all European countries. In the 9 countries for which data 
are available, between 1 % and 26 % of all opioid users in 
treatment receive interventions not involving opioid 
substitution (Figure 3.7).
 l Prisons: low availability of hepatitis C treatment
Prisoners report higher lifetime rates of drug use and more 
harmful patterns of use (including injecting) than the 
general population, making prisons an important setting 
for drug-related interventions. Many prisoners have 
complex healthcare needs, and assessment of drug use 
and drug-related problems is an important part of the 
health screening at prison entry in many countries.
Two important principles for the implementation of health 
interventions in prison are equivalence with provision in 
community settings and continuity of care after prison 
release. The availability of opioid substitution treatment in 
prisons is reported by 28 of the 30 countries monitored by 
the EMCDDA. Detoxification, individual and group 
counselling, and therapeutic communities or special 
inpatient wards are available in most countries. Many 
European countries have established interagency 
partnerships between prison health services and providers 
in the community, in order to facilitate delivery of health 
education and treatment interventions in prison and to 
ensure continuity of care upon prison entry and release.
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Infectious diseases testing (HIV, HBV, HCV) is available in 
prisons in most countries, although the provision of 
hepatitis C treatment is rare. Hepatitis B vaccination 
programmes are reported to exist in 16 countries. The 
provision of clean injecting equipment is less common, 
with only 4 countries reporting the existence of syringe 
programmes in this setting.
Preparation for prison release, including social 
reintegration, is carried out in most countries. Programmes 
to prevent the risk of drug overdose, particularly high 
among opioid injectors in the period after leaving prison, 
are reported in 5 countries and include training and 
information and the provision of naloxone upon prison 
release.
 l Hospital emergencies: multiple substances implicated
Hospital emergency data can provide an insight into acute 
drug-related harms. Information is available from the 
European Drug Emergencies Network (Euro-DEN Plus), 
which monitors drug-related presentations in 15 (sentinel) 
hospitals in 9 European countries. The 5 054 presentations 
recorded by the project in 2015 had a median age of 
31 years, and most were male (77 %).
On average about 1.5 drugs were reported per 
presentation (7 768 in total) (see Figure 3.8). Nearly two 
thirds of presentations (65 %) involved the use of 
established drugs, and the most common were heroin, 
cocaine, cannabis, GHB/GBL, amphetamine and MDMA; 
one quarter (24 %) involved the misuse of prescription or 
over the counter drugs (most commonly opioids and 
benzodiazepines); and 9 % involved new psychoactive 
substances (up from 6 % in 2014). Half of the 
presentations for new psychoactive substances involved a 
synthetic cathinone and 14 % a synthetic cannabinoid. The 
drugs involved in emergency presentations differed 
between sites, reflecting local patterns of use. For 
example, emergencies related to heroin were the most 
common presentations in Dublin (Ireland) and Oslo 
(Norway), whereas presentations related to GHB/GBL, 
cocaine and MDMA were predominant in London (United 
Kingdom).
FIGURE 3.8
Top 20 drugs recorded in emergency presentations in sentinel hospitals in 2015 
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The majority (80 %) of those presenting with acute drug 
toxicity were discharged from hospital within 12 hours; a 
small minority (6 %) developed severe toxicity requiring 
admission to critical care and 4 % were admitted to a 
psychiatric ward. Around half (9) of the 17 deaths recorded 
involved opioids.
Only a few countries have monitoring systems in place that 
allow a national analysis of trends in acute drug 
intoxications. Among these, acute heroin emergencies 
have increased in the United Kingdom, but continued to 
decline in the Czech Republic and Denmark, where 
methadone emergencies are increasing. In Lithuania, 
opioid-related emergencies almost doubled between 2013 
and 2015. In Spain, cocaine is involved in about half of the 
reported drug-related emergencies, and the trend is 
stabilising after a decline, while cannabis emergencies are 
continuing to increase. Slovenia also reports an upward 
trend in cannabis emergencies. In the Netherlands, half of 
the cases presenting at first aid stations at festivals (51 %) 
involved MDMA and the proportion is decreasing. 
Methamphetamine-related emergency cases, recorded by 
sentinel centres in the Czech Republic, increased by more 
than 50 % between 2014 and 2015.
 l New drugs: high potency and harms
New psychoactive substances, including new synthetic 
opioids, synthetic cannabinoids and synthetic cathinones, 
are causing a range of serious harms in Europe.
Fentanyls are exceptionally potent opioids which, although 
playing a small role in Europe’s drug market, pose a 
serious threat to individual and public health. In part this 
stems from the increased risk of severe and fatal 
poisonings in users — often manifesting as outbreaks — 
as fentanyls cause rapid and profound respiratory 
depression. It is also because of the increased risk of 
accidental exposure resulting in poisoning in others; 
families and friends of users, as well as law enforcement, 
other emergency services, medical staff and those working 
in laboratories, may be at risk. The use of protective 
equipment to reduce the risk of harm from accidental 
exposure may be necessary in some settings, such as 
customs facilities at Europe’s borders, where seizures of 
bulk fentanyl powders may be handled. Additionally, there 
is some evidence to suggest that fentanyls have been sold 
to unsuspecting users as established illicit drugs and fake 
pain medicines, potentially increasing the risk of severe 
and fatal poisoning in some user groups. In such 
circumstances, the availability of the antidote naloxone 
may need to be assessed. In addition to the acute risks of 
overdose, fentanyls also have high abuse liabilities and 
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dependence-producing potentials, which could worsen 
public health and social problems commonly associated 
with high-risk opioid use.
During 2016, the EMCDDA and Europol launched special 
investigations into acryloylfentanyl and furanylfentanyl, 
after signals were detected through the EU Early Warning 
System. More than 50 deaths were reported, many of 
which were attributed directly to these substances. In 
addition, the EMCDDA also issued five alerts to its network 
across Europe related to these and other new fentanyls.
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The synthetic cannabinoids are another group of new 
substances that continued to cause problems in 2016. The 
EMCDDA issued alerts on three substances — MDMB-
FUBINACA, MDMB-CHMICA and 5F-MDMB-PINACA — 
based on 45 serious adverse events, including 18 deaths 
and 27 non-fatal intoxications. In addition, the EMCDDA 
launched a procedure which led to a risk assessment of 
MDMB-CHMICA, which ultimately resulted in the 
substance being been subjected to control measures 
throughout Europe (see box).
 l New drugs: developing response skills
The harms associated with new drugs bring a new set of 
challenges to frontline responders. A recent EMCDDA 
analysis found that European health professionals in 
various settings (treatment, prevention and harm 
reduction) rely predominantly on professional experience 
acquired in response to established illicit drugs and on the 
interventions used in that context. These interventions 
include dissemination of educational material, provision of 
sterile injecting equipment or symptomatic management 
of acute emergency cases. Often, evidence-based 
interventions may be adjusted to account for specific 
toxicities, to reflect socio-cultural characteristics of risk 
groups (e.g. party-goers, men who have sex with men) or 
respond to particular risk behaviours (e.g. increased 
access to syringes to respond to high injecting frequency) 
associated with new psychoactive substances. A need for 
professional training, guidance and competence building 
activities on responding to new drugs was also highlighted 
in the analysis.
Delivering interventions targeting hard-to-reach drug-using 
populations experiencing significant harms related to new 
psychoactive substances, such as men who have sex with 
men, homeless people and prison inmates is a particular 
challenge. In some countries, increased use of synthetic 
cannabinoids among prisoners has caused concern due to 
the impact on mental health, the strong withdrawal effects 
and increasing levels of associated violence. 
Multidisciplinary responses and collaborations involving a 
range of health providers across intervention settings (e.g. 
sexual health clinics or custodial settings and drug 
treatment centres) appear to be an important feature of 
adequate health responses to harms related to use of new 
psychoactive substances in Europe.
 l Chronic drug-related harms: HIV declines but local outbreaks continue
Drug users, particularly those who inject drugs, are at risk 
of contracting infectious diseases through the sharing of 
drug use material and through unprotected sex. Drug 
injection continues to play a central role in the 
transmission of blood-borne infections such as the 
hepatitis C virus (HCV) and, in some countries, the human 
immunodeficiency virus (HIV). In 2015, 1 233 new HIV 
diagnoses in people infected through injecting drug use 
were notified in the European Union (Figure 3.9), 
representing 5 % of diagnoses for which the route of 
transmission is known. This proportion has remained low 
and stable for the last decade. New HIV infections among 
people who inject drugs have declined in most European 
countries, with an overall decrease of 41 % between 2007 
and 2015. However, injecting drug use remains an 
important mode of transmission in some countries: in 
2015, a quarter or more of newly diagnosed HIV cases 
were attributed to injecting drug use in Lithuania (34 %), 
Latvia (32 %), Luxembourg (27 %) and Estonia (25 %).
Risk assessment of MDMB-CHMICA
In July 2016, MDMB-CHMICA became the first 
synthetic cannabinoid to be risk-assessed by the 
EMCDDA. It was first reported to the EU Early 
Warning System in 2014 by Hungary, and was 
subsequently detected in 23 EU Member States, 
Turkey and Norway. The substance was involved in 
more than 20 serious poisonings and 28 deaths.
Bulk powders of MDMB-CHMICA are produced in 
China and imported into Europe, where they are 
processed and packaged into ‘herbal smoking 
mixtures’. It is thought that many of the adverse 
events caused by MDMB-CHMICA and other 
synthetic cannabinoids are related to the high 
potency of these substances and poor 
manufacturing practices. Evidence suggests that 
producers guess the quantities of substance to apply 
when manufacturing ‘smoking mixtures’. In addition, 
the crude manufacturing techniques used may not 
distribute the substance uniformly in the product. 
This may lead to some samples containing elevated 
amounts of the substance, resulting in high doses 
and an increased risk of severe poisoning and death.
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While a majority of countries reported decreases in 
injecting-related HIV cases between 2014 and 2015, 
Germany, Ireland and the United Kingdom reported rises to 
levels not seen for 7 to 8 years. In Ireland and the United 
Kingdom, this was in part related to localised outbreaks of 
new HIV infections among people who inject drugs. 
Luxembourg also reported an outbreak in 2014. Increased 
stimulant injection, alongside high levels of user 
marginalisation, have been common factors in these 
outbreaks. In addition, the injection of stimulant drugs in a 
sexual context (‘slamming’) among small groups of men 
who have sex with men has been linked to an increased 
risk of infection transmission.
In 2015, 14 % of new AIDS cases in the European Union, 
for which the route of transmission was known, were 
attributed to injecting drug use. The 479 injection-related 
notifications represent just over a quarter of the number 
reported a decade ago. Many of the cases were reported in 
Greece, Latvia and Romania, where HIV testing and 
treatment responses require further strengthening.
 l HCV prevalence: national variation
Viral hepatitis, particularly infection caused by the hepatitis 
C virus (HCV), is highly prevalent among injecting drug 
users across Europe. For every 100 people infected with 
HCV (antibody-positive), 75 to 80 will develop chronic 
infection. This has important long-term consequences, as 
chronic HCV infection, often worsened by heavy alcohol 
use, will lead to increasing numbers of deaths and cases 
of severe liver disease, including cirrhosis and cancer, 
among an ageing population of high-risk drug users.
FIGURE 3.9
Newly diagnosed HIV cases related to injecting drug use: overall and selected trends and most recent data
<3 3.1–6 6.1–9 9.1–12 >12Cases per million population
NB: Data for 2015 (source: ECDC).
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The prevalence of antibodies to HCV, indicating present or 
past infection, among national samples of injecting drug 
users in 2014–15, varied from 16 % to 84 %, with 5 out of 
the 13 countries with national data reporting a rate in 
excess of 50 % (Figure 3.10). Among the countries with 
national trend data for the period 2010–15, declining HCV 
prevalence in injecting drug users was reported in 4 
countries, while 3 observed an increase.
Among drug users, hepatitis B virus (HBV) infection is less 
common than HCV infection. For this virus, however, the 
presence of the HBV surface antigen indicates a current 
infection, which may be acute or chronic. In the 7 countries 
with national data, between 1.7 % and 11 % of drug 
injectors were estimated to be currently infected with HBV.
Drug injection is a risk factor for other infectious diseases, 
and drug-related clusters of hepatitis A were reported in 
the Czech Republic, Germany and Luxembourg in 2016. 
Clusters and sporadic cases of wound botulism among 
injecting drug users were also reported in Germany, 
Norway and the United Kingdom.
 l Infectious diseases: prevention measures
The main approaches taken to reduce drug-related 
infectious diseases among people who inject drugs 
include the provision of opioid substitution treatment, 
sterile injecting equipment, injection risk behaviour 
counselling, hepatitis B vaccination, infectious disease 
testing, hepatitis treatment and HIV treatment.
For those who inject opioids, being in substitution 
treatment significantly lowers infection risk, with some 
analyses indicating increasing protective effects when high 
treatment coverage is combined with high levels of syringe 
provision. Evidence shows that needle and syringe 
programmes are effective in reducing the transmission of 
HIV among people who inject drugs. Of the 30 countries 
monitored by the EMCDDA, all except Turkey provide clean 
injecting equipment at specialised outlets free of charge. 
However, considerable differences exist between countries 
regarding the geographical distribution of syringe outlets 
and the coverage of the target population by the 
intervention (Figure 3.11). Information on the provision of 
syringes through specialised programmes is available from 
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25 countries, which together report the distribution of over 
52 million syringes in 2014/15. This is a major 
underestimation, as several large countries, such as 
Germany, Italy and the United Kingdom, do not report full 
national data on syringe provision.
Establishing links between drug and sexual health service 
providers may be particularly important for responding 
effectively to problems linked to the injection of stimulants 
by men who have sex with men. Important prevention 
interventions for this group include testing and treatment 
of infections, health education and the distribution of 
prevention materials, including condoms and sterile 
injecting equipment. To prevent sexually acquired HIV 
infection, pre-exposure prophylaxis is an additional 
prevention option for populations at highest risk.
 l Increasing early HIV diagnosis: extended testing opportunities
Late HIV diagnosis — when the infection has already 
begun to damage the immune system — is a particular 
problem for people who inject drugs. In 2015, 58 % of 
newly notified injecting-related transmissions were 
diagnosed late. This compares with an EU average of 47 % 
diagnosed late for all routes of transmission. Late HIV 
diagnosis is associated with increased morbidity and 
mortality, and delays in initiation of anti-retroviral therapy. 
The policy of ‘test-and-treat’ for HIV, whereby anti-retroviral 
therapy is started directly after a HIV diagnosis, results in a 
reduction of transmission and is especially important 
among groups with higher risk behaviours, such as people 
who inject drugs. Early diagnosis and initiation of anti-
retroviral therapy, offers those infected a normal life 
expectancy.
In many countries, community-based and low-threshold 
drug services are providing and extending HIV testing 
opportunities with the aim of increasing testing uptake and 
earlier detection of infections. EU minimum quality 
standards promote voluntary testing for blood-borne 
infectious diseases at community agencies alongside 
counselling on risky behaviours and assistance to manage 
illness. However, stigma and marginalisation of drug users 
remain important barriers to uptake of testing and 
treatment.
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 l HCV treatment: more effective medications
As HCV infection is highly prevalent among people who 
inject drugs in Europe, they are a key target for testing and 
treatment, in order to prevent liver disease progression and 
deaths. Moreover, reducing the number of people who can 
transmit the infection, by offering HCV treatment, is an 
essential component of a comprehensive prevention 
response. European clinical guidelines recommend that all 
patients with chronic liver disease due to HCV infection 
must be considered for therapy. The guidelines also 
recommend that treatment should be considered without 
delay in individuals at risk of transmitting the virus 
(including active injecting drug users) and that HCV 
treatment should be provided to drug users on an 
individualised basis and delivered in a multidisciplinary 
setting.
Since 2013, effective, better tolerated, all-oral, interferon-
free regimens with direct-acting antiviral agents are 
becoming the mainstay of the treatment of HCV infection. 
Furthermore, treatment with these medicines may be 
offered in specialised drug services in community settings, 
which may increase uptake and availability. Many 
European countries are adopting new viral hepatitis 
strategies, updating treatment guidelines and improving 
HCV testing and linkage to care. However, challenges 
remain, such as low levels of testing, unclear referral and 
treatment pathways in many countries, and the high cost 
of the new drugs.
 l Overdose deaths: recent increases
Drug use is a recognised cause of avoidable mortality 
among European adults. Studies on cohorts of high-risk 
drug users commonly show total mortality rates in the 
range of 1–2 % per year. Overall, opioid users in Europe are 
5 to 10 times more likely to die than their peers of the 
same age and gender. Increased mortality among opioid 
users is primarily related to overdose, but other causes of 
death indirectly related to drug use, such as infections, 
accidents, violence and suicide, are also important. 
Ill-health, marked by accumulated and interlinked 
conditions is common. Chronic pulmonary and liver 
conditions as well as cardio-vascular problems are 
frequent and account for an increased share of deaths 
among the older and chronic drug users.
In Europe, drug overdose continues to be the main cause 
of death among high-risk drug users, and over three 
quarters of overdose victims are male (78 %). Overdose 
data, especially the European cumulative total, must be 
interpreted with caution. Among the reasons for this are 
systematic under-reporting in some countries and 
registration processes that result in reporting delays. 
Annual estimates therefore represent a provisional 
minimum value.
It is estimated that at least 7 585 overdose deaths, 
involving at least one illicit drug, occurred in the European 
Union in 2015. This rises to an estimated 8 441 deaths if 
Norway and Turkey are included, representing a 6 % 
increase from the revised 2014 figure of 7 950, and 
increases have been reported in almost all age bands 
(Figure 3.12). As in previous years, the United Kingdom 
(31 %) and Germany (15 %) together account for around 
half of the European total. This relates partly to the size of 
the at-risk populations in these countries, but also to the 
under-reporting in some other countries. Focusing on 
countries with relatively robust reporting systems, revised 
data for 2014 confirm an increase in the number of 
overdose deaths in Spain, while increases in the number of 
overdose deaths reported in 2014 in Lithuania and the 
United Kingdom have continued into 2015, and increases 
are also now reported in Germany and the Netherlands. A 
continued upward trend is also observed in Sweden, 
though it may be partly due to the combined effects of 
changes in investigation, coding and reporting practices. 
Turkey is continuing to report increases, but this appears to 
be largely driven by improvements in data collection and 
reporting.
Reflecting the ageing nature of Europe’s opioid-using 
population, who are at greatest risk of drug overdose 
death, the reported number of overdose deaths increased 
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among older age groups between 2007 and 2015, while 
those among younger age groups decreased. However, 
10 % of the overdose cases are younger than 25 years, and 
there has recently been a slight increase in the number of 
overdose deaths reported among those aged under 25 in 
several countries including Sweden and Turkey.
 l Opioid-related deaths fuel overall increase
Heroin or its metabolites, often in combination with other 
substances, are present in the majority of fatal overdoses 
reported in Europe. The most recent data show an increase 
in the number of heroin-related deaths in Europe, notably 
in the United Kingdom. In England and Wales, heroin or 
morphine was mentioned in 1 200 deaths registered in 
2015, representing a 26 % increase on the previous year 
and a 57 % increase in relation to 2013. Deaths related to 
heroin also increased in Scotland (United Kingdom), 
Ireland and Turkey. Other opioids are also regularly found 
in toxicological reports. These substances, primarily 
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methadone and buprenorphine, but also fentanyls and 
tramadol, are associated with a substantial share of 
overdose deaths in some countries. According to the most 
recent data, the number of recorded methadone-related 
deaths exceeded heroin-related deaths in Croatia, 
Denmark, France and Ireland.
Stimulants such as cocaine, amphetamines, MDMA and 
cathinones are implicated in a smaller number of overdose 
deaths in Europe, although their significance varies by 
country. In the United Kingdom (England and Wales), 
deaths involving cocaine increased from 169 in 2013 to 
320 in 2015, although many of these are thought to be 
heroin overdoses among people who also used crack. In 
Spain, where cocaine-related deaths have been stable for 
some years, the drug continued to be the second most 
often cited illicit drug in overdose deaths in 2014 (269 
cases). In 2015, stimulant-related deaths in Turkey 
included 56 cases associated with cocaine, 206 cases 
with amphetamines and 166 cases with MDMA (62 of 
which were attributed to use of MDMA alone). Synthetic 
cannabinoids were reported in 137 cases in Turkey, 63 of 
which were attributed solely to the use of these drugs.
 l Mortality rates highest in northern Europe
The mortality rate due to overdoses in Europe in 2015 is 
estimated at 20.3 deaths per million population aged 
15–64. The rate among males (32.3 cases per million 
males) is almost four times that among females (8.4 cases 
per million females). Overdose mortality rates peak at age 
35–39 for males and age 30–34 for females. Mean age at 
death, however, is lower among males: 38 compared with 
41 among females. National mortality rates and trends vary 
considerably (Figure 3.13), and are influenced by factors 
such as prevalence and patterns of drug use as well as by 
national practices of reporting, recording information and 
coding overdose cases in national mortality databases. 
According to the latest data available, rates of over 40 
deaths per million population were reported in 8 northern 
European countries, with the highest rates reported in 
Estonia (103 per million), Sweden (100 per million), 
Norway (76 per million) and Ireland (71 per million) 
(Figure 3.13).
 l Preventing overdoses and drug-related deaths
Reducing fatal drug overdoses and other drug-related 
deaths is a major public health challenge in Europe. 
Targeted responses in this area focus either on preventing 
the occurrence of overdoses, or on improving the likelihood 
of surviving an overdose.
A meta-analysis of observational studies supports the 
effectiveness of methadone substitution treatment in 
reducing mortality (overdose and all causes) among 
opioid-dependent people. The mortality rate of clients in 
methadone treatment was less than a third of the 
expected rate in opioid users out of treatment. Analysis of 
risk of death at different stages of treatment suggests a 
need to focus interventions at the start of treatment 
(during the first 4 weeks, in particular with methadone) 
and once it has finished. After the conclusion of treatment, 
the first 4 weeks are associated with a higher risk of 
overdose. This suggests patients who frequently enter and 
leave treatment are particularly vulnerable to overdose.
Supervised drug consumption facilities aim both to 
prevent overdoses from occurring and to ensure 
professional support is available if an overdose occurs. 
Such facilities currently operate in 6 EU countries and 
Norway; 78 facilities in total. In 2016, 2 consumption 
rooms opened in France for a 6-year trial, and new 
facilities were established in Denmark and Norway.
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 l Naloxone: new products being developed
Naloxone is an opioid antagonist medication that can 
reverse opioid overdose and is used in hospital emergency 
departments and by ambulance personnel. In recent years, 
there has been a growth in the provision of ‘take-home’ 
naloxone to opioid users, their partners, peers and families, 
alongside training in recognising and responding to 
overdose. Naloxone has also been made available for use 
by staff of services that regularly come into contact with 
drug users. Take-home naloxone programmes currently 
exist in 10 European countries. Naloxone kits provided by 
drugs and health services generally include syringes 
pre-filled with the medication, although in Denmark and 
Norway an adaptor allows naloxone to be administered 
intra-nasally. In France, a new nasal formulation of the 
medication has been granted a temporary authorisation for 
use. After being scaled up in community settings since 
2013, naloxone take-home provision in Estonia was 
extended to prisons in 2015. A recent systematic review of 
the effectiveness of take-home naloxone found evidence 
that its provision in combination with educational and 
training interventions reduces overdose-related mortality. 
Some populations with an elevated risk of overdose, such 
as recently released prisoners, may particularly benefit, 
and an evaluation of the national naloxone programme in 
the United Kingdom (Scotland) found that it was 
associated with a significant reduction in the proportion of 
opioid-related deaths that occurred within a month of 
prison release.
FIGURE 3.13
Drug-induced mortality rates among adults (15–64): selected trends and most recent data
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Annex: national data tables
OPIOIDS
High-risk opioid use 
estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment entrants % opioids clients injecting (main route of administration)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country Year of estimate
cases per 
1 000 % (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – – 27.7 (3 234) 10.3 (411) 37.4 (2 773) 14 (409) 8.3 (31) 14.9 (374) 16 681
Bulgaria – – 84.8 (1 530) 64.5 (207) 96 (932) 73 (772) 69.9 (116) 75.5 (580) 3 423
Czech 
Republic
2015 1.8–1.9 17 (1 720) 7 (333) 25.9 (1 387) 82.6 (1 412) 79.8 (264) 83.2 (1 148) 4 000
Denmark – – 13 (613) 5.5 (124) 20.6 (472) 26.6 (121) 10.5 (11) 31.4 (108) 6 268
Germany 2014 2.7–3.3 32.9 (28 669) 13.3 (3 552) 41.4 (25 117) 32.6 (11 392) 29.4 (1 549) 33.2 (9 843) 77 200
Estonia – – 93.3 (263) 87.3 (55) 95 (153) 70.7 (183) 67.3 (37) 82.2 (125) 1 166
Ireland – – 47.6 (4 515) 25.9 (971) 62.4 (3 403) 38.2 (1 672) 30.9 (293) 39.9 (1 318) 9 917
Greece 2015 2.1–2.8 69.8 (2 836) 52.9 (834) 80.8 (1 984) 32.4 (914) 26.6 (221) 34.9 (690) 10 082
Spain 2014 1.6–2.6 24.6 (12 032) 10.5 (2 486) 42.9 (8 056) 13.7 (1 568) 7.4 (178) 15.2 (1 173) 61 859
France 2013–14 4.4–7.4 28 (13 744) 15 (2 378) 48.9 (8 310) 18.5 (2 150) 12.3 (263) 21.1 (1 505) 168 840
Croatia 2015 2.5–4.0 81.3 (6 124) 20.8 (176) 89.1 (5 917) 72.1 (4 377) 36.5 (62) 73.2 (4 299) 5 061
Italy 2015 4.6–5.9 53.3 (25 144) 38.8 (8 040) 64.6 (17 104) 50.8 (10 620) 39.5 (2 521) 55.8 (8 099) 60 047
Cyprus 2015 1.9–3.2 25.7 (205) 11.5 (50) 44.2 (142) 48 (97) 46 (23) 48.9 (68) 252
Latvia 2014 3.4–7.5 53.5 (402) 32.7 (128) 76.1 (274) 92.3 (370) 82.8 (106) 96.7 (264) 609
Lithuania 2007 2.3–2.4 89 (2 268) 66.1 (261) 94 (1 991) 87.2 (1 970) 89.3 (233) 87 (1 724) 596
Luxembourg 2007 5–7.6 56.2 (163) 25 (6) 57.9 (125) 43 (68) 16.7 (1) 42.7 (53) 1 078
Hungary 2010–11 0.4–0.5 3.6 (156) 1.6 (46) 8.4 (93) 53.5 (77) 48.9 (22) 56 (51) 669
Malta 2015 5.6–6.5 73.2 (1 296) 28.7 (66) 79.8 (1 230) 61.9 (760) 43.9 (25) 62.8 (735) 1 026
Netherlands 2012 1.1–1.5 11.5 (1 262) 6.2 (402) 19.3 (860) 6.1 (39) 7.6 (13) 5.6 (26) 7 421
Austria 2015 5.3–5.6 55.4 (2 016) 26.9 (351) 71.4 (1 665) 32.3 (516) 23 (73) 34.5 (443) 17 599
Poland 2014 0.4–0.7 16.3 (1 465) 4.8 (208) 27.6 (1 224) 62.1 (902) 40.8 (84) 65.6 (800) 2 564
Portugal 2012 4.2–5.5 49.2 (1 357) 28.9 (458) 76.8 (899) 16.6 (209) 9.9 (40) 19.8 (169) 17 011
Romania – – 32.6 (1 057) 17.3 (360) 66.3 (686) 88.2 (834) 85.6 (286) 90 (543) 547
Slovenia 2015 3.4–4.1 74.7 (236) 42 (37) 87.7 (199) 44.5 (105) 24.3 (9) 48.2 (96) 3 261
Slovakia 2008 1.0–2.5 24.1 (602) 14.8 (179) 33.6 (414) 68.5 (402) 51.4 (91) 75.7 (305) 600
Finland 2012 3.8–4.5 51.7 (339) 38.3 (106) 61.5 (233) 73.3 (247) 65.7 (69) 76.7 (178) 3 000
Sweden (1) – – 25.2 (8 907) 16.8 (2 101) 29.5 (6 562) – – – 3 679
United 
Kingdom
2010–11 7.9–8.4 49.7 (59 763) 21.7 (8 595) 63.5 (50 984) 31.8 (13 125) 17.5 (929) 34 (12 139) 142 085
Turkey 2011 0.2–0.5 74.2 (8 073) 67.5 (3 627) 80.7 (4 446) 24.7 (1 994) 15.5 (561) 32.2 (1 433) 12 500
Norway (2) 2013 2.0–4.2 17 (1 005) – – – – – 7 498
European 
Union
– – 37.6 (181 918) 18.3 (32 921) 51.4 (143 189) 36.6 (55 311) 28.2 (7 550) 39 (46 856) 626 541
EU, Turkey 
and Norway
– – 38.2 (190 996) 19.8 (36 548) 52 (147 635) 36 (57 305) 26.7 (8 111) 38.8 (48 289) 646 539
Data on clients in substitution treatment are for 2015, or most recent year available: Denmark, Finland, Netherlands and Spain, 2014; Turkey, 2011.
(1) First-time and previously treated entrants available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all 
entrants.
(2) The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.
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COCAINE
Prevalence estimates Entrants into treatment during the year
General population School population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15–64) 
Last 12 
months, 
young 
adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All clients
First-
time 
entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium (1) 2013 – 0.9 3 18.9 (2 207) 18.9 (756) 18.9 (1 401) 6.5 (125) 1.1 (7) 9.4 (116)
Bulgaria 2012 0.9 0.3 5 1.6 (29) 6.5 (21) 0.8 (8) 7.1 (2) 0 (0) 25 (2)
Czech 
Republic
2015 1.8 0.3 1 0.3 (27) 0.3 (12) 0.3 (15) 0 (0) 0 (0) 0 (0)
Denmark 2013 5.2 2.4 2 5.5 (260) 5.9 (134) 5.4 (124) 3.9 (8) – 8.6 (8)
Germany (3) 2015 3.8 1.2 3 6 (5 209) 5.6 (1 494) 6.1 (3 715) 17.1 (2 843) 8.8 (353) 19.7 (2 490)
Estonia 2008 – 1.3 1 0.7 (2) – 1.2 (2) 50 (1) – 50 (1)
Ireland 2015 7.8 2.9 3 10.5 (996) 13.7 (513) 8.4 (457) 0.8 (8) 0.2 (1) 1.6 (7)
Greece – – – 1 6.6 (269) 8.9 (141) 5.2 (128) 11.6 (31) 4.3 (6) 19.5 (25)
Spain 2015 9.1 3.0 2 36.5 (17 864) 34.8 (8 234) 37 (6 954) 1.3 (224) 0.7 (56) 2.1 (141)
France 2014 5.4 2.4 4 6.1 (3 013) 6.1 (963) 8.1 (1 369) 10.2 (269) 3.6 (32) 16.5 (198)
Croatia 2015 2.7 1.6 2 1.4 (104) 2.8 (24) 1.2 (80) 2 (2) – 2.5 (2)
Italy 2014 7.6 1.8 3 25.3 (11 935) 30.4 (6 296) 21.3 (5 639) 4.2 (479) 2.6 (159) 5.9 (320)
Cyprus 2016 1.4 0.4 3 10 (80) 8.3 (36) 11.8 (38) 5.1 (4) 0 (0) 7.9 (3)
Latvia 2015 1.5 1.2 2 1.2 (9) 1.8 (7) 0.6 (2) 0 (0) 0 (0) 0 (0)
Lithuania 2012 0.9 0.3 2 0.6 (15) 1.8 (7) 0.3 (7) 13.3 (2) 14.3 (1) 14.3 (1)
Luxembourg – – – – 19 (55) 16.7 (4) 20.4 (44) 44.4 (24) – 50 (22)
Hungary (3) 2015 1.2 0.9 2 2.3 (99) 2.5 (75) 1.7 (19) 5.2 (5) 1.4 (1) 15.8 (3)
Malta 2013 0.5 – 3 15.9 (281) 39.6 (91) 12.3 (190) 17.6 (45) 8.1 (7) 22.4 (38)
Netherlands 2015 5.1 3.6 2 24.3 (2 675) 20.8 (1 357) 29.6 (1 318) 0.4 (5) 0.1 (1) 0.6 (4)
Austria 2015 3 0.4 2 7.1 (258) 9.6 (125) 5.7 (133) 6.3 (15) 0.8 (1) 11.6 (14)
Poland 2014 1.3 0.4 4 2.1 (189) 1.9 (83) 2.3 (101) 2.2 (4) 1.3 (1) 3 (3)
Portugal 2012 1.2 0.4 2 12 (331) 15.1 (239) 7.9 (92) 4.4 (13) 2.3 (5) 9.6 (8)
Romania 2013 0.8 0.2 3 0.6 (19) 0.9 (18) 0 (0) 0 (0) 0 (0) –
Slovenia 2012 2.1 1.2 2 4.1 (13) 9.1 (8) 2.2 (5) 23.1 (3) 0 (0) 60 (3)
Slovakia 2015 0.7 0.3 2 0.8 (19) 0.7 (9) 0.7 (9) 5.9 (1) – 12.5 (1)
Finland 2014 1.9 1.0 1 0 (0) 0 (0) 0 (0) – – –
Sweden (4,5) 2013 – 1.2 2 0.9 (318) 1.7 (211) 0.5 (103) 0 (0) 0 (0) 0 (0)
United 
Kingdom (2,4)
2015 9.7 4.0 2 13.9 (16 673) 17.2 (6 830) 12.2 (9 806) 1.5 (168) 0.4 (18) 2.3 (146)
Turkey 2011 – – – 1.8 (198) 1.5 (79) 2.2 (119) – – –
Norway (4) 2015 4.2 2.2 1 1.4 (83) – – – – –
European 
Union
– 5.2 1.9 – 13 (62 949) 15.4 (27 688) 11.4 (31 759) 6.5 (4 281) 2.4 (649) 10 (3 556)
EU, Turkey 
and Norway
– – – – 12.6 (63 230) 15 (27 767) 11.2 (31 878) 6.5 (4 281) 2.4 (649) 10 (3 556)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, 
Latvia data may not be comparable.
(1) Prevalence estimates for the general population refer to Flanders only.
(2) Prevalence estimates for the general population refer to England and Wales only.
(3) Age range for prevalence estimates in the general population: 18–64, 18–34.
(4) Age range for prevalence estimates in the general population: 16–64, 16–34. 
(5) First-time and previously treated entrants are available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all 
entrants.
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AMPHETAMINES
Prevalence estimates Entrants into treatment during the year
General population School population
Amphetamines clients as % of treatment 
entrants
% amphetamines clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young 
adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium (1) 2013 – 0.5 2 9.9 (1 160) 8.6 (345) 10.7 (794) 13.5 (130) 3.9 (11) 17.8 (118)
Bulgaria 2012 1.2 1.3 6 4.7 (84) 15.9 (51) 1.6 (16) 2 (1) 0 (0) 0 (0)
Czech 
Republic
2015 4.4 2.2 1 69.7 (7 033) 75.1 (3 550) 65 (3 483) 78.1 (5 446) 73.8 (2 586) 82.6 (2 860)
Denmark 2013 6.6 1.4 1 6.6 (311) 6.2 (140) 7.1 (163) 4 (11) 1.7 (2) 6.2 (9)
Germany (3,4) 2015 3.6 1.9 4 16.8 (14 646) 19.3 (5 134) 15.7 (9 512) 2.2 (719) 1.5 (168) 2.5 (551)
Estonia 2008 – 2.5 2 2.1 (6) 3.2 (2) 2.5 (4) 66.7 (4) 100 (2) 50 (2)
Ireland 2015 4.1 0.6 3 0.6 (59) 0.9 (33) 0.4 (24) 3.4 (2) 3 (1) 4.2 (1)
Greece – – – 2 0.4 (18) 0.4 (7) 0.4 (11) 0 (0) 0 (0) 0 (0)
Spain 2015 3.6 1.0 1 1.3 (655) 1.6 (385) 1.1 (209) 0.9 (6) 1.1 (4) 0.5 (1)
France 2014 2.2 0.7 2 0.5 (264) 0.5 (84) 0.6 (108) 11.6 (26) 14.9 (11) 15.6 (15)
Croatia 2015 3.5 2.3 3 1.4 (102) 2.7 (23) 1.1 (74) – – –
Italy 2014 2.8 0.6 2 0.2 (91) 0.3 (59) 0.1 (32) 5.2 (4) 6.4 (3) 3.3 (1)
Cyprus 2016 0.5 0.1 3 4.9 (39) 3.9 (17) 5.6 (18) 2.6 (1) 5.9 (1) 0 (0)
Latvia 2015 1.9 0.7 3 16.2 (122) 21.5 (84) 10.6 (38) 67.5 (81) 62.2 (51) 78.9 (30)
Lithuania 2012 1.2 0.5 1 2.5 (63) 7.1 (28) 1.5 (31) 26.7 (16) 3.7 (1) 45.2 (14)
Luxembourg – – – – 0.3 (1) – 0.5 (1) – – –
Hungary (4) 2015 1.7 1.4 3 11.4 (489) 12 (354) 8.9 (98) 9.6 (46) 5.7 (20) 23.7 (23)
Malta 2013 0.3 – 2 0.3 (5) 0.4 (1) 0.3 (4) 20 (1) – 25 (1)
Netherlands 2015 4.7 3.1 2 7.4 (817) 7.5 (487) 7.4 (330) 1.3 (4) 1 (2) 1.9 (2)
Austria 2015 2.2 0.9 3 4.8 (174) 5.7 (75) 4.2 (99) 3.8 (6) 2.9 (2) 4.3 (4)
Poland 2014 1.7 0.4 4 24.3 (2 194) 25.4 (1 091) 23.8 (1 056) 3.7 (80) 1.7 (18) 5.8 (60)
Portugal 2012 0.5 0.1 1 0.1 (4) 0.3 (4) – 0 (0) 0 (0) –
Romania 2013 0.3 0.1 1 0.4 (12) 0.3 (7) 0.3 (3) 0 (0) 0 (0) 0 (0)
Slovenia 2012 0.9 0.8 1 1.3 (4) 4.5 (4) 0 (0) 0 (0) 0 (0) –
Slovakia 2015 1.4 0.8 1 45.2 (1 132) 44.7 (539) 45.4 (559) 28.7 (315) 24.3 (129) 34 (183)
Finland 2014 3.4 2.4 1 15.2 (100) 16.2 (45) 14.5 (55) 77.6 (76) 62.8 (27) 89.1 (49)
Sweden (3,5,6) 2013 – 1.3 1 7 (2 645) 8.3 (1 129) 5.8 (1 376) – – –
United 
Kingdom (2,5)
2015 10.3 0.9 1 2.8 (3 332) 3.6 (1 414) 2.4 (1 913) 18.9 (382) 11 (89) 24.3 (293)
Turkey 2011 0.1 0.1 – 1.8 (196) 2.5 (133) 1.1 (63) 0.5 (1) 0.8 (1) 0 (0)
Norway (3,5) 2015 3.1 0.3 1 13.9 (823) – – – – –
European 
Union
– 3.8 1.1 – 7.4 (35 562) 8.4 (15 092) 7.2 (20 011) 15.1 (7 357) 16.8 (3 128) 14.1 (4 217)
EU, Turkey 
and Norway
– – – – 7.3 (36 581) 8.2 (15 225) 7.1 (20 074) 15 (7 358) 16.6 (3 129) 14.1 (4 217)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, 
Latvia data may not be comparable.
(1) Prevalence estimates for the general population refer to Flanders only.
(2) Prevalence estimates for the general population refer to England and Wales only.
(3) Entrants into treatment refer to clients with stimulants other than cocaine, not just amphetamines.
(4) Age range for prevalence estimates in the general population: 18–64, 18–34.
(5) Age range for prevalence estimates in the general population: 16–64, 16–34. 
(6) First-time and previously treated entrants are available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all 
entrants.
TABLE A3
4th proof - embargo  
6 June 12.45 CET (11.45 WET)
86
European Drug Report 2017: Trends and Developments
MDMA
Prevalence estimates Entrants into treatment during the year
General population School population MDMA clients as % of treatment entrants
Year of survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count)
Belgium (1) 2013 – 0.8 3 0.3 (36) 0.6 (25) 0.1 (11)
Bulgaria 2012 2.0 2.9 5 0.2 (3) 0.6 (2) 0.1 (1)
Czech 
Republic
2015 6.3 3.5 3 0 (4) 0.1 (3) 0 (1)
Denmark 2013 2.3 0.7 1 0.3 (15) 0.5 (11) 0.2 (4)
Germany (3) 2015 3.3 1.3 2 – – –
Estonia 2008 – 2.3 3 – – –
Ireland 2015 9.2 4.4 4 0.5 (47) 0.8 (31) 0.3 (15)
Greece – – – 1 0.2 (7) 0.2 (3) 0.2 (4)
Spain 2015 3.6 1.3 1 0.3 (133) 0.5 (111) 0.1 (13)
France 2014 4.2 2.3 2 0.4 (188) 0.5 (76) 0.3 (49)
Croatia 2015 3.0 1.4 2 0.4 (32) 0.8 (7) 0.3 (23)
Italy 2014 3.1 1.0 3 0.2 (80) 0.2 (40) 0.2 (40)
Cyprus 2016 1.1 0.3 3 – – –
Latvia 2015 2.4 0.8 3 0.3 (2) 0.3 (1) 0.3 (1)
Lithuania 2012 1.3 0.3 2 0.1 (3) 0.3 (1) 0.1 (2)
Luxembourg – – – – – – –
Hungary (3) 2015 4.0 2.1 2 2 (85) 1.8 (54) 1.9 (21)
Malta 2013 0.7 – 2 0.9 (16) 1.7 (4) 0.8 (12)
Netherlands 2015 8.4 6.6 3 0.7 (80) 1 (67) 0.3 (13)
Austria 2015 2.9 1.1 2 0.5 (20) 1.1 (14) 0.3 (6)
Poland 2014 1.6 0.9 3 0.3 (23) 0.3 (14) 0.2 (9)
Portugal 2012 1.3 0.6 2 0.3 (8) 0.4 (7) 0.1 (1)
Romania 2013 0.9 0.3 2 0.5 (16) 0.8 (16) 0 (0)
Slovenia 2012 2.1 0.8 2 0.3 (1) 1.1 (1) 0 (0)
Slovakia 2015 3.1 1.2 3 0.1 (3) 0.1 (1) 0.2 (2)
Finland 2014 3.0 2.5 1 0.5 (3) 1.1 (3) 0 (0)
Sweden (4) 2013 – 1.0 1 – – –
United 
Kingdom (2,4)
2015 9.4 3.1 3 0.4 (490) 0.8 (312) 0.2 (174)
Turkey 2011 0.1 0.1 – 1 (106) 1.4 (77) 0.5 (29)
Norway (4) 2015 2.3 1.2 1 – – –
European 
Union
– 4.2 1.8 – 0.3 (1 295) 0.4 (804) 0.1 (402)
EU, Turkey and 
Norway
– – – – 0.3 (1 401) 0.5 (881) 0.2 (431)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, 
Latvia data may not be comparable.
(1) Prevalence estimates for the general population refer to Flanders only.
(2) Prevalence estimates for the general population refer to England and Wales only.
(3) Age range for prevalence estimates in the general population: 18–64, 18–34.
(4) Age range for prevalence estimates in the general population: 16–64, 16–34.
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CANNABIS
Prevalence estimates Entrants into treatment during the year
General population School population Cannabis clients as % of treatment entrants
Year of survey
Lifetime, 
adults 
(15–64)
Last 12 
months, 
young adults 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count)
Belgium (1) 2013 15 10.1 17 31.9 (3 737) 51.6 (2 065) 21.3 (1 582)
Bulgaria 2012 7.5 8.3 27 3.2 (58) 8.4 (27) 0.7 (7)
Czech 
Republic
2015 29.5 18.8 37 11.8 (1 195) 16.4 (776) 7.8 (419)
Denmark 2013 35.6 17.6 12 70.9 (3 338) 79 (1 783) 62.5 (1 430)
Germany (3) 2015 27.2 13.3 19 39.1 (34 108) 56.9 (15 168) 31.2 (18 940)
Estonia 2008 – 13.6 25 3.5 (10) 7.9 (5) 1.2 (2)
Ireland 2015 27.9 13.8 19 28.3 (2 681) 45.2 (1 693) 16.8 (918)
Greece – – – 9 19.4 (789) 34.2 (539) 9.8 (240)
Spain 2015 31.5 17.1 27 33.7 (16 478) 48.1 (11 386) 16.4 (3 084)
France 2014 40.9 22.1 31 60.4 (29 621) 74.9 (11 855) 37.6 (6 391)
Croatia 2015 19.4 16.0 21 12.8 (967) 62 (526) 6.5 (432)
Italy 2014 31.9 19.0 27 19.5 (9 225) 28 (5 810) 12.9 (3 415)
Cyprus 2016 12.1 4.3 7 58.8 (469) 75.9 (330) 38 (122)
Latvia 2015 9.8 10.0 17 23.3 (175) 35.5 (139) 10 (36)
Lithuania 2012 10.5 5.1 18 3.5 (89) 11.9 (47) 1.6 (33)
Luxembourg – – – – 23.1 (67) 58.3 (14) 19.9 (43)
Hungary (3) 2015 7.4 3.5 13 56.2 (2 420) 62.7 (1 854) 41.4 (458)
Malta 2013 4.3 – 13 8.9 (158) 29.1 (67) 5.9 (91)
Netherlands 2015 25.6 16.1 22 47.3 (5 202) 55.5 (3 625) 35.4 (1 577)
Austria 2015 23.6 14.1 20 29.2 (1 063) 54.4 (711) 15.1 (352)
Poland 2014 16.2 9.8 24 28 (2 525) 36.3 (1 558) 20.3 (901)
Portugal 2012 9.4 5.1 15 33.9 (934) 50.8 (806) 10.9 (128)
Romania 2013 4.6 3.3 8 39.3 (1 272) 54.8 (1 137) 9.5 (98)
Slovenia 2012 15.8 10.3 25 14.2 (45) 38.6 (34) 4.8 (11)
Slovakia 2015 15.8 9.3 26 24.6 (616) 35.7 (430) 13.7 (169)
Finland 2014 21.7 13.5 8 20.7 (136) 35.7 (99) 9.8 (37)
Sweden (4,5) 2015 14.7 7.3 7 11.1 (3 924) 16.9 (2 113) 7.9 (1 752)
United 
Kingdom (2,4)
2015 29.4 11.3 19 25.9 (31 129) 46.3 (18 345) 15.8 (12 686)
Turkey 2011 0.7 0.4 – 6 (653) 7.7 (416) 4.3 (237)
Norway (4) 2015 20.9 8.6 7 27.2 (1 609) – –
European 
Union
– 26.3 13.9 –
31.5 
(152 431)
46.2 (82 942) 19.9 (55 354)
EU, Turkey and 
Norway
– – – – 30.9 (154 693) 45.1 (83 358) 19.6 (55 591)
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, 
Latvia data may not be comparable.
(1) Prevalence estimates for the general population refer to Flanders only.
(2) Prevalence estimates for the general population refer to England and Wales only.
(3) Age range for prevalence estimates in the general population: 18–64, 18–34.
(4) Age range for prevalence estimates in the general population: 16–64, 16–34.
(5) First-time and previously treated entrants are available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all 
entrants.
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OTHER INDICATORS
Drug-induced deaths 
(aged 15–64)
HIV diagnoses attributed 
to injecting drug use 
(ECDC)
Injecting drug use estimate
Syringes distributed 
through specialised 
programmes
Country cases per million population (count)
cases per million 
population (count)
Year of 
estimate
cases per 
1 000 
population
count
Belgium 9 (67) 1.3 (15) 2015 2.3–4.6 1 034 242
Bulgaria 4 (17) 3.6 (26) – – 364 111
Czech Republic 6 (39) 0.4 (4) 2015 6.1–6.4 6 421 095
Denmark 58 (210) 1.4 (8) – – –
Germany 22 (1 185) 1.7 (134) – – –
Estonia 103 (88) 41.9 (55) 2009 4.3–10.8 2 136 691
Ireland (1) 71 (213) 10.8 (50) – – 393 275
Greece 0 (0) 6.4 (70) 2015 0.6–1.0 268 157
Spain (1) 15 (455) 2.1 (96) 2014 0.2–0.3 1 483 399
France (1) 7 (294) 0.9 (58) 2014 2.1–3.2 12 314 781
Croatia 19 (54) 0.5 (2) 2012 0.4–0.6 923 650
Italy 8 (304) 1.8 (112) – – –
Cyprus 15 (9) 1.2 (1) 2015 0.3–0.7 164
Latvia 14 (18) 44.3 (88) 2012 7.3–11.7 524 949
Lithuania 59 (115) 15.1 (44) – – 200 630
Luxembourg 31 (12) 24.9 (14) 2009 4.5–6.9 361 392
Hungary 4 (25) 0.2 (2) 2015 1 188 696
Malta 28 (8) 0 (0) – – 340 644
Netherlands 16 (182) 0.1 (1) 2008 0.2–0.2 –
Austria 26 (152) 2.6 (22) – – 5 953 919
Poland 9 (249) 1 (37) – – 10 142
Portugal 6 (39) 4.2 (44) 2012 1.9–2.5 1 004 706
Romania 2 (21) 7.1 (142) – – 1 425 592
Slovenia 22 (30) 0.5 (1) – – 500 757
Slovakia 7 (27) 0.6 (3) – – 347 162
Finland 43 (150) 1.3 (7) 2012 4.1–6.7 5 301 000
Sweden 100 (618) 1.5 (15) 2008–11 1.3 281 397
United 
Kingdom (2)
60 (2 528) 2.8 (182) 2004–11 2.9–3.2 –
Turkey 10 (533) 0.2 (13) – – –
Norway 76 (257) 1.5 (8) 2014 2.2–3.0 2 500 192
European Union 21.3 (7 109) 2.4 (1 233) – – –
EU, Turkey and 
Norway
20.3 (7 899) 2.1 (1 254) – – –
Caution is required when comparing drug-induced deaths due to issues of coding, coverage and under-reporting in some countries.
(1) Syringes distributed through specialised programmes refer to 2014.
(2) UK syringe data: England, no data; Scotland, 4 376 456 and Wales, 3 398 314 (both in 2015); Northern Ireland, 292 390 (2014).
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Annex I National data tables
SEIZURES
Heroin Cocaine Amphetamines MDMA
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count kg count tablets (kg) count
Belgium 121 2 375 17 487 4 330 73 3 260 59 696 (9) 1 739
Bulgaria 265 – 9 – 73 – 17 284 (<0.01) –
Czech Republic 2 76 120 113 127 1 125 3 110 (0.4) 133
Denmark 29 571 548 3 470 193 2 626 70 244 (10) 1 005
Germany 210 3 061 3 114 3 592 1 423 13 680 967 410 (0) 4 015
Estonia <0.01 2 4 60 119 391 41 549 (13) 239
Ireland – 758 – 364 – 63 – (0) 204
Greece 567 2 957 102 575 3 118 300 (0) 56
Spain 256 7 755 21 621 38 273 360 4 500 135 110 (0) 2 958
France 818 4 692 10 869 9 483 486 1 027 1 325 305 (0) 1 592
Croatia 145 154 12 359 15 597 – (7) 747
Italy 768 2 230 4 035 5 403 26 278 17 573 (11) 406
Cyprus <0.01 8 107 95 1.68 55 173 (1) 50
Latvia 3 142 4 62 36 763 238 (3) 154
Lithuania 2 368 533 16 62 205  (1) 11
Luxembourg 8 208 11 190 0.27 13 543 (0) 14
Hungary 12 48 31 153 34 706 56 420 (7) 287
Malta 4 35 21 156 <0.01 2 1 404 (0.01) 46
Netherlands – – – – – – – (–) –
Austria 70 605 120 1 190 70 1 088 10 148 (3) 512
Poland 4 – 219 – 747 – 120 886 (78) –
Portugal 97 763 6 029 1 079 2 111 35 484 (2) 180
Romania 334 335 71 119 0.4 55 13 852 (0.1) 280
Slovenia 6 273 3 178 3 – 2 908 (2) –
Slovakia 3 63 2 42 5 819 1 460 (0) 40
Finland 0.4 – 9 – 300 – 23 660 (0) –
Sweden 8 483 114 2 086 546 5 398 95 421 (35) 2 095
United Kingdom 806 8 083 4 228 15 588 491 4 517 812 127 (2) 3 030
Turkey 8 294 12 271 511 941 4 057 2 336 5 673 901 (0) 5 012
Norway 62 1 178 85 1 332 628 7 304 116 353 (27) 1 241
European Union 4 537 36 045 69 421 86 976 5 196 41 397 3 812 305 (212) 19 793
EU, Turkey and 
Norway
12 893 49 494 70 017 89 249 9 880 51 037 9 602 559 (185) 26 046
Amphetamines refers to both amphetamine and methamphetamine.
All data are for 2015. Data for Scotland (UK) are not available.
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SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity seized Number of seizures Quantity seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count plants (kg) count
Belgium 7 045 5 569 764 26 401 – (–) –
Bulgaria 13 – 1 176 – 9 811 (37 775) –
Czech Republic 8 105 655 3 672 30 770 (0) 361
Denmark 3 619 14 680 616 1 214 14 560 (464) 545
Germany 1 599 6 059 3 852 32 353 154 621 (0) 2 167
Estonia 812 21 60 597 0 (12) 44
Ireland – 192 – 1 049 – (–) 182
Greece 330 542 2 474 5 499 59 242 (0) 735
Spain 380 361 164 760 15 915 156 984 379 846 (0) 2 029
France 60 790 65 503 16 835 32 446 153 895 (0) –
Croatia 12 764 409 4 546 5 687 (0) 270
Italy 67 825 7 684 9 286 5 838 138 013 (0) 1 566
Cyprus 3 21 226 777 2 814 (0) 58
Latvia 1 272 63 71 712 – (20) 17
Lithuania 591 32 143 456 – (–) –
Luxembourg 1 130 20 1 040 81 (0) 10
Hungary 18 141 590 1 945 4 659 (0) 127
Malta 70 132 4 106 28 (0) 8
Netherlands – – – – 9 940 000 (0) –
Austria 287 2 038 851 11 426 – (687) 379
Poland 843 – 1 830 – 103 339 (0) –
Portugal 2 412 4 180 224 582 6 102 (0) 298
Romania 5 178 180 1 987 – (293) 90
Slovenia 3 109 458 3 103 14 006 (0) 167
Slovakia 27 33 70 1 204 2 085 (0) 35
Finland 63 – 208 – 23 000 (125) –
Sweden 1 065 8 897 1 054 9 619 – (–) –
United Kingdom 7 219 5 959 30 680 100 811 399 230 (0) 9 735
Turkey 7 855 3 750 45 816 29 652 0 (0) 2 471
Norway 2 015 11 394 255 4 411 0 (69) 339
European Union 536 293 287 792 88 649 404 362 11 441 789 (39 376) 18 823
EU, Turkey and 
Norway
546 163 302 936 134 719 438 425 11 441 789 (39 445) 21 633
All data are for 2015. Data for Scotland (UK) are not available. 
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About this report
The Trends and Developments report presents a 
top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Statistical Bulletin and 30 Country Drug Reports, 
it makes up the 2017 European Drug Report package.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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